   medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
     (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                         It is made available under a CC-BY-NC-ND 4.0 International license .
 1     Global projections of potential lives saved from COVID-19 through
 2     universal mask use
 3     IHME COVID-19 Forecasting Team
 4     Abstract
 5     Background: Social distancing mandates have been effective at reducing the health impacts of COVID-
 6     19. The ensuing economic downturns and unemployment increases have led many nations to
 7     progressively relax mandates. As COVID-19 transmission and deaths rise in many low and middle-income
 8     countries (LMICs), with continuing widespread transmission elsewhere, policymakers are searching for
 9     options to reduce COVID-19 mortality without re-imposing strict social distancing mandates.
10     Methods: Using a Bayesian meta-regression of 40 studies measuring the impact of mask use on
11     respiratory viral infections, we estimated the reduction in transmission associated with the use of cloth
12     or paper masks used in a general population setting. We used data from daily surveys conducted by
13     Facebook, YouGov, and Premise, on the proportion of people reporting always wearing a mask outside
14     their home for nearly all countries. We predicted deaths and infections until January 1st 2021 under a
15     reference and universal mask use scenario using a deterministic transmission dynamics model with
16     categories for susceptible, exposed, infected and recovered (SEIR). In the reference scenario, we assume
17     continued easing of mandates but with action to re-impose mandates for a period of six weeks, at a
18     level of eight daily deaths per million population. The universal mask scenario assumed scaling up of
19     mask use to 95% over a one-week period.
20     Findings: Use of simple masks can reduce transmission of COVID-19 by 40% (95% uncertainty interval
21     [UI] 20% â€“ 54%). Universal mask use would lead to a reduction of 815,600 deaths (95% UI 430,600 to
22     1,491,000 deaths) between August 26th 2020 and January 1st 2021, the difference between the
23     predicted 3.00 million deaths (95% UI 2.20 to 4.52 million) in the reference and 2.18 million deaths (95%
                                                                            1
          NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

   medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
     (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                         It is made available under a CC-BY-NC-ND 4.0 International license .
24     UI 1.71 to 3.14 million) in the universal mask scenario over this time period. Mask use was estimated at
25     59.0% of people globally on August 18th, ranging from 41.9% in North Africa and the Middle East to
26     79.2% in Latin America and the Caribbean. The effect of universal mask use is greatest in countries such
27     as India (158,832 fewer deaths in universal mask scenario, 95% UI 75,152 to 282,838 deaths), the United
28     States of America (93,495 fewer deaths; 95% UI 59,329 to 150,967 deaths), and Russia (68,531 fewer
29     deaths; 95% UI 34,249 to 145,960 deaths).
30     Interpretation: The rising toll of the COVID-19 pandemic can be substantially reduced by the universal
31     adoption of masks. This low-cost policy, whether customary or mandated, has enormous health benefits
32     and likely large economic benefits as well, by delaying the need for re-imposition of social distancing
33     mandates.
34
                                                                          2

   medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
     (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                         It is made available under a CC-BY-NC-ND 4.0 International license .
35     Research in context
36     Evidence before this study
37     One meta-analysis of 21 studies reported a pooled reduction in the risk of respiratory virus infection of
38     47% (95% CI 36-79%) from a subset of eight studies reporting on mask use in non-health workers but it
39     did not distinguish type of mask. Another meta-analysis reported on 26 studies of mask use in health
40     workers and three studies in non-healthcare settings, reported a pooled effect of a 66% (55-74%)
41     reduction in infections and a reduction by 44% (21-60%) in the three non-healthcare setting studies.
42     Several survey series regularly measure self-reported mask use but results from these different sources
43     have not previously been pooled to derive daily estimates of mask use over the course of the epidemic.
44     Global models of the impact of scaled up mask use have to our knowledge not been published.
45     Added value of this study
46     We combined the studies on mask use identified in the two meta-analyses and added one further study.
47     In a Bayesian meta-regression approach, we derived the effect of simple cloth or paper masks used
48     outside of a healthcare setting. In the meta-regression we make use of all the information provided by
49     all of these studies, rather than subsetting to just those studies that provided the direct comparison of
50     interest. Pooling estimates on the prevalence of self-reported mask use from three survey series
51     provides up-to-date information on trends in mask use in almost all countries. We use extensive survey
52     data covering nearly every country in the world to assess recent trends and current mask use. We then
53     use an SEIR transmission dynamics model with good predictive validity to assess the potential of scaled
54     up mask use to reduce global mortality from COVID-19.
55     Implications of all the available evidence
56     Universal mask use can save many lives and avoid or, at least, delay the need for re-imposition of social
57    mandates (such as stay-at-home orders, curfews, etc.), which would also contribute to ameliorating the
58    negative effects of COVID-19 on the economy and unemployment. Until an affordable vaccine becomes
59    universally available, mandating mask use is the most attractive policy option available to all countries,
                                                                          3

   medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
     (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                         It is made available under a CC-BY-NC-ND 4.0 International license .
60     particularly if an expected increased transmission risk occurs in the Northern hemisphereâ€™s fall and
61     winter. Simple face coverings are cheap and effective; one of the few available interventions that is
62     widely available to everyone. Countries with currently low mask use will need to determine the optimal
63     balance between encouraging the use of masks through advocacy and information about their benefits,
64     and governance of a compulsory use associated with penalties for non-compliance.
65
                                                                          4

   medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
     (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                         It is made available under a CC-BY-NC-ND 4.0 International license .
66     Introduction
67     COVID-19 has spread to all regions of the world and as of August 30th 2020, with over 25 million cases
68     and 845,414 deaths have been reported globally1. This is undoubtedly an underestimate and only one
69     direct measure, among many, that may be used to refer to the impact of the pandemic on health and
70     health systems around the world. In March 2020, nearly all nations put in place a set of social distancing
71     mandates that have contributed to blunting the effects of COVID-19. Economic downturns and the
72     associated mass unemployment caused by these measures has led most nations to progressively relax
73     social distancing mandates. As COVID-19 transmission and deaths rise in many low and middle-income
74     countries (LMICs) and some high-income countries, policymakers are keen to identify policy options to
75     reduce COVID-19 mortality without re-imposing strict social distancing mandates.
76     One attractive strategy is the imposition of mandates requiring the wearing of masks in public spaces
77     when physical distancing is not feasible. Initially, the World Health Organization (WHO) discouraged
78     mask use by public questioning of the evidence supporting general use and arguing it might lead to mask
79     shortages for healthcare providers2,3. Several systematic reviews, however, have suggested that cloth
80     and other non-medical masks worn by the general public can markedly reduce transmission.4,5 A
81     growing number of national and local governments have recently adopted mask use mandates, with
82     now over 150 countries mandating mask use either nationally, or in specific transmission hotspots,
83     focused in enforcing their use within on public transit or indoor public spaces.6 In nations such as the
84     United States (US) and Brazil, mask use has become a political issue, with widely varying viewpoints on
85     the ethics, legality and enforcement of mask use mandates.7,8 Evidence of the individual benefits,
86     population health impacts, and the potential economic benefits of increased mask use may be a useful
87     input in these national debates.
88     Masks can affect the transmission of respiratory pathogens in a number of ways, thereby providing a
89     complement to stringent social distancing mandates without the associated severe economic impacts,
                                                                          5

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
 90     and in settings such as indoor public spaces where distancing may not be possible. Simple cloth masks
 91     are also affordable and equitably accessible. At the individual level masks reduce transmission via a
 92     physical barrier whereby the force of exhalation, coughing, or sneezing leads to impaction and
 93     interception of viral droplets (> 5Âµm in diameter) and aerosol (â‰¤ 5 Âµm in diameter, resulting from
 94     evaporation of expired droplets, also described as droplet nuclei) onto the fibers of the mask.9â€“11 Given
 95     greater impaction efficiency for droplets, masks are most effective in blocking outward exhalation12,
 96     although evidence from studies of air pollution aerosol indicates some protection of non-medical masks
 97     in blocking a small fraction of aerosol inhalation.13 Thus mask wearing is effective both for the infected
 98     and the uninfected14 and is also relevant to the recent discussions regarding airborne transmission of
 99     SARS-CoV-2.15 Airborne transmission is, by definition, caused by droplet nuclei (i.e. evaporated droplets)
100     that may remain infectious when suspended in the air over extended distances or time periods.11 As
101     masks can effectively block exhalation of droplets, they also reduce production of droplet nuclei by
102     evaporation, and therefore offer a practical intervention against airborne transmission to complement
103     ventilation and less widely accessible interventions such as air filtration and UV disinfection.
104     In this paper, we provide a meta-regression of the reduction in transmission associated with mask use,
105     use survey data to assess current levels and trends in use of masks globally, and quantify the benefits of
106     universal mask use (here defined as 95% of individuals always wearing a mask when outside their home)
107     on COVID-19 mortality using a COVID-19 transmission dynamics model. We provide estimates of lives
108     saved through universal mask use globally and at the national level between July 26th 2020 and January
109     1st 2021.
110
                                                                           6

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
111     Methods
112     Our analysis is comprised of three main components: a literature scoping analysis and meta-regression
113     of the benefits of mask use with an emphasis on non-medical mask use amongst the general (non-
114     healthcare) population; an analysis of survey data on the levels and trends in mask use; and modeling
115     two scenarios (reference and universal mask use) of COVID-19 incidence and death using a deterministic
116     transmission dynamics model with categories for susceptible, exposed, infected and recovered (SEIR).
117     Each component is discussed in more detail below.
118     Estimating the effectiveness of masks in preventing transmission
119     We performed a meta-regression of 63 observations from 40 studies of the effectiveness of masks in
120     preventing the transmission of respiratory virus infections. These studies were included in two published
121     meta-analyses4,5 with one further study of mask use for COVID-19 in the general population added.16
122     The studies varied in setting (general population versus healthcare), type of mask (which we
123     dichotomized into medical-grade masks, including surgical and N95 masks, and non-medical masks,
124     including cloth masks), comparator group (no mask use or â€œoccasionalâ€ mask use), type of diagnosis
125     (clinical or laboratory), country of study (dichotomized into Asian and non-Asian countries) and type of
126     respiratory virus (SARS-CoV-1 or 2 versus H1N1, influenza, or other respiratory viruses); details on the
127     details of all included studies16â€“55 can be found in SI Table 2 in the Appendix. From the identified papers,
128     we extracted all relevant observations that assessed mask effectiveness, allowing for multiple
129     observations per study based on variations in mask type, virus studied, or comparison group. From the
130     two meta-analyses, four identified studies were excluded where a relative risk was not available56,57, we
131     were unable to extract mask use from general PPE use58, or because the comparison group was of less
132     protective masks rather than no or infrequent mask use59. In order to derive the most relevant pooled
133     estimate for the effect of mask use on preventing the spread of COVID-19 in populations, we performed
134     a meta-regression of all 63 observations and their characteristics to predict the effect of non-medical
                                                                           7

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
135     mask use in a community setting to prevent laboratory-confirmed SARS-CoV-2 compared to no use of
136     masks. For studies with zero counts in the numerator, we used a continuity correction of 0.001 to
137     estimate the RR in order to ensure inclusion in our analyses; sensitivity analyses considering other
138     continuity corrections produced highly consistent results (see Appendix). To generate summary
139     estimates we used a custom Bayesian mixed-effects meta-regression tool (MR-BRT â€“ â€œmeta-regression â€“
140     Bayesian, regularized, trimmedâ€)60 which accounted for between-study heterogeneity in the width of
141     the uncertainty interval (see Appendix for more details).
142     Past, current and future prevalence of mask use
143     We used three main sources of data on self-reported use of masks: the Facebook Global Symptom
144     Survey61, the PREMISE surveys62, and the YouGov COVID-19 Behaviour Tracker surveys.63 Between April
145     23rd and August 18th, Facebook has surveyed 23.3 million Facebook users from 102 countries using an
146     instrument with multiple items on behaviours related to COVID-19, including mask use. For the US, we
147     used data collected through PREMISE. There were 190,216 total PREMISE responses representing all 50
148     states and the District of Columbia with responses collected between April 21st and August 21st. The
149     YouGov surveys cover 29 countries and have interviewed around 493,400 individuals since March 1st and
150     up until August 8th 2020. From the Facebook surveys, we used the item: â€œIn the last 7 days, how often
151     did you wear a mask when in public?â€ to which there are the following responses â€œAll of the time; Most
152     of the time; About half of the time; Sometimes; Never; I have not been in public during the last 7 daysâ€.
153     Respondents for â€œAll of the timeâ€ were the numerator in our proportion. From the PREMISE surveys, we
154     use the following question: â€œWhen you leave your home do you typically wear a face mask
155     (SELECT_ONE)â€ with responses â€œYes, always; Yes, sometimes; No neverâ€. Respondents for â€œYes, alwaysâ€
156     were the numerator in our proportion. From YouGov, we use the following question: â€œThinking about
157     the last 7 days, have you worn a face mask outside your home (e.g. when on public transport, going to a
                                                                           8

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
158     supermarket, going to a main road)â€ with responses â€œAlwaysâ€, â€œFrequentlyâ€, â€œSometimesâ€, â€œRarelyâ€, and
159     â€œNot at allâ€. Respondents for â€œAlwaysâ€ were the numerator in our proportion.
160     Mask use for each location was estimated using a spline-based smoothing process. This smoothing
161     process averages each data point with five neighboring data points. To arrive at smooth, flat values at
162     the ends of the observed data, we computed the average of the change in mask use over the three
163     following days (left tail) and three preceding days (right tail). For locations without data on mask use, we
164     used, in order of preference, national level estimates (for subnational locations), regional estimates, and
165     super-regional estimates based on the regional groupings used by the Global Burden of Disease Study
166     (GBD). The only exception was for countries in Oceania, a region where no data are available through
167     any of the three survey platforms. In the GBD hierarchy, these countries are part of the East Asia and
168     Southeast Asia super-region; however, mask use in Oceania is likely to be more similar to mask use in
169     Australia and New Zealand and so the mask use from that region was used for countries in Oceania.
170     To construct our scenario of universal mask use, we assume that current mask use in all locations would
171     increase to 95% over the course of 7 days. We use 95% as that is the highest level of mask use reported
172     at the national level to date during the COVID-19 pandemic; this level was reported in Singapore. Our
173     â€œuniversal mask useâ€ scenario assumes that this level of mask use can be achieved through the adoption
174     and enforcement of mask use mandates around the world.
175     COVID-19 SEIR model construction for each location
176     The IHME COVID-19 prediction model has been described in detail elsewhere.64 For the results
177     presented in this analysis, the SEIR part of the model are most relevant. We construct an SEIR model for
178     each location we model; the Appendix shows the basic states included in the model and the transition
179     parameters. The critical driver of the epidemic is the rate at which susceptible individuals become
180     infected in each location which is assumed to be represented as:
                                                                           9

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
                                                              ğ‘‘ğ‘‘ğ‘‘ğ‘‘              ğ‘†ğ‘†(ğ¼ğ¼1 + ğ¼ğ¼2 )ğ›¼ğ›¼
190                                                                = âˆ’ğ›½ğ›½(ğ‘¡ğ‘¡)
                                                              ğ‘‘ğ‘‘ğ‘‘ğ‘‘                     ğ‘ğ‘
181     Where Î²t is the transmission parameter for time period t, ğ›¼ğ›¼ represents a mixing coefficient to account
182     for imperfect mixing within each location, S is the fraction of each locationâ€™s population that is
183     susceptible, and I1 and I2 is the fraction that are infectious. Effective Rt, the number of new infections
184     caused by each case is a simple monotonic transformation of Î²t and the fraction of the population that is
185     susceptible. We use an efficient algorithm to directly estimate Î²t in the past â€“ see appendix for details.
186     To determine the strength of the relationship between Î² t and various covariates, we perform a log-
187     linear regression using the open source mixed effects solver SLIME5. All covariates are assumed to have
188     fixed effects while the intercept is allowed to vary by location. For location ğ‘™ğ‘™, the regression is calculated
189     as:
191                                                             lnï¿½ğ›½ğ›½ğ‘ğ‘,ğ‘™ğ‘™ ï¿½ = ğ›¼ğ›¼0,ğ‘™ğ‘™ + ğ‘¿ğ‘¿ğ‘™ğ‘™ ğœ¶ğœ¶
192     where ğ›¼ğ›¼0,ğ‘™ğ‘™ is the random intercept for location ğ‘™ğ‘™, ğ‘¿ğ‘¿ğ‘™ğ‘™ is a matrix with a column for each covariate in the
193     regression and a row for each day, and ğœ¶ğœ¶ is the coefficient indicating the strength of the relationship
194     between log ğ›½ğ›½ and each of the covariates. We tested many covariates and included the following in the
195     model: population density measured as the share of the population living in areas with more than 2,500
196     individuals per square kilometer, the fraction of the population living below 100 meters above sea level,
197     smoking prevalence, particulate matter air pollution (PM2.5 population-weighted annual average
198     concentration), mobility measured using cell phone apps, mask use, COVID-19 testing per capita, and
199     pneumonia seasonality. Pneumonia seasonality was constructed as an index using medical certification
200     of cause of death data on pneumonia deaths by week and normalized annually. In locations without 4-
201     or 5-star quality cause of death data65, we used latitude as a predictor of the pattern of pneumonia
202     seasonality. To avoid over-estimating the effects of pneumonia seasonality and mask use we used
203     constraints on each in the regression â€“ see Appendix for details. Specifically, for mask use, we did not let
                                                                              10

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
204     the regression estimate an effect size larger than what was consistent with the mask use meta-analysis
205     of the individual level effect. To capture uncertainty in the input data, model parameters and regression
206     coefficients linking Î²jt to covariates, we generated 1,000 models for each location â€“ see Appendix for
207     details.
208     We evaluated out of sample predictive validity for this modeling approach by holding out the last five
209     weeks of data and compared predictions from the held-out data to what occurred; median absolute
210     percent error for cumulative deaths at five weeks was 7%.66 We also compared this model to other
211     COVID-19 prediction models that make their estimates publicly available; overall, we find that our model
212     has the best performance at 5- and 6-weeks out-of-sample.66
213     We used the set of 1,000 SEIR models for each location to generate two types of scenarios: a reference
214     scenario and a universal mask use scenario. In the reference scenario, or what we think is most likely to
215     occur, key drivers such as mobility and testing per capita evolve according to past trends â€“ see Appendix
216     for details. In the universal mask use scenario, we assume that mask mandates and other campaigns
217     lead to scale-up of mask use to 95% within seven days of enactment. We also assume both in the
218     reference and in the universal mask use scenario that social distancing mandates would be re-imposed
219     when the daily death rate reaches eight per million people per day. This daily death rate represents the
220     90th percentile across countries of the observed daily death rate in the past few months before each
221     country imposed the maximum number of social distancing mandates. This daily death rate also
222     represents the observed average daily death rate to date among the small number of locations that are
223     experiencing a resurgence and are re-imposing social distancing mandates.
                                                                          11

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
224     Results
225     Figure 1 shows the relative risk of viral respiratory infection among users of different types of
226     facemasks. Studies of general population use (13 observations of 63 total) included cluster randomized
227     trials of household member mask use living with an infected individual, cohort analyses of close contacts
228     of infected individuals, and case control analyses of mask use prior to infection amongst the general
229     population or of secondary infections amongst household members of an infected individual. A total of
230     19 observations were of non-medical masks, with eight of these focused on use by the general public.
231     The meta-regression suggested the benefits of non-medical masks in the general population to be a 40%
232     (UI 20% â€“ 54%) reduction in transmission. The benefits of wearing surgical or medical masks in the
233     general population were slightly larger, a 43% reduction (23% - 59%) in transmission. Even larger
234     reductions in transmission were estimated for non-medical (54% [40%-64%] and medical (56% [48%-
235     64%]) mask use amongst healthcare worker populations. More details are provided in the Appendix.
236     Based on survey data collected through smartphone hosted questionnaires, Figure 2 shows a map of
237     mask use by location as of August 18th, the last date of fully observed data in the model. Mask use is
238     high in most parts of Latin America and South-East and East Asia. The highest mask use on August 18th
239     was in Chile (93.6%), followed by Puerto Rico (93.5%), and Guatemala (92.2%). The lowest rates are seen
240     in Northern Europe (Sweden, Norway, and Denmark < 1%) and North Africa (Tunisia 6.5%). Lower rates
241     are seen in some parts of sub-Saharan Africa, Northern Europe, and states and provinces in the United
242     States, Canada, and Australia. Mask use is highest among people who live in cities and lowest in people
243     who live in rural communities (see Appendix).
244     Figure 3 shows the global and super-region trends in mask use since the beginning of the epidemic.
245     Mask use data start only in the beginning of April so the rapid expansion from likely a very low baseline
246     pre-COVID-19 outside of East Asia most probably occurred in March. Mask use was estimated at 59.0%
247     of people globally on August 18th, ranging from 41.9% in North Africa and the Middle East to 79.2% in
                                                                          12

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
248     Latin America and the Caribbean (Figure 3). Mask use has increased in some locations where mandates
249     have been put into place such as Australia, Belgium, and the United Kingdom (SI Figure 7). Mask use has
250     declined in some settings where death rates are declining such as Poland, Czechia, and Italy (SI Figure 7).
251     Mask use varied by gender in some regions, with higher use by females in all regions except for South
252     Asia, (globally 54.2% in females vs to 52.3% in males) and by age with generally lower use amongst 18-
253     24 year olds (50.0%) and those over 65 years (46.4%) compared to 55-54 year old adults (56.5%) who
254     were the most likely to wear masks (percentages on July 21, see Appendix).
255     Global projections of COVID-19 deaths with and without a universal mask use mandate are shown in
256     Figure 4. In our reference scenario, we expect daily COVID-19 deaths to increase in October through
257     December leading to 3.00 million deaths (95% UI 2.20 to 4.52 million) by January 1st 2021. Uncertainty in
258     daily deaths and cumulative deaths widens steadily over time such that there is considerable
259     uncertainty in global deaths by January 1st. In contrast, the universal mask use scenario leads to a mean
260     estimate of 2.18 million deaths (95% UI 1.71 to 3.14 million) by January 1st. The difference in mortality
261     between the reference and universal mask use scenario suggests that 0.82 million lives (95% UI 0.43 to
262     1.49 million) could be saved over this time period if 95% of people were to always wear masks when
263     outside their home. Table 1 provides estimates by location of the expected deaths in the reference and
264     universal mask use scenario along with the number of deaths saved through the mask use mandate. The
265     countries where mask mandates would have the largest effect are populous countries such as India
266     (158,832 fewer deaths in universal mask scenario, 95% UI 75,152 to 282,838 deaths), the United States
267     of America (93,495 fewer deaths; 95% UI 59,329 to 150,967 deaths), and Russia (68,531 fewer deaths;
268     95% UI 34,249 to 145,960 deaths). The greatest magnitude difference in mortality rate occurred in the
269     Netherlands (23,282 fewer deaths, 136 deaths per 100,000), Switzerland (6,062 fewer deaths, 86 deaths
270     per 100,000).
                                                                          13

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
271     Figure 5 shows a map of the percent reduction in expected deaths from the reference scenario
272     compared to the mask use scenario in the deaths from August 28th to January 1st. The largest percent
273     reduction in expected deaths occurred in Tanzania (80.4% difference, 95% UI 63.4 to 94.4%), Poland
274     (78.8% difference, 95% UI 60.4 to 93.5%), and Algeria (78.4% difference, 95% UI 61.9 to 92.2%).
275     Expected deaths were greater in the universal mask use scenario than in the reference scenario in some
276     locations due to the delay in re-imposition of mandates such as in Kazahkstan (more deaths in mask use
277     scenario, 95% UI 7.2 to 45.3% increase). There are large variations in the number of lives saved globally,
278     regionally, nationally, and subnationally and these are detailed in full in Table 1.
279
280     Discussion
281     Wearing a mask reduces the risk of contracting COVID-19 for individuals by 40% (20%-54%). Given global
282     mask use is currently at 59.0%, increasing mask use to 95% through mandates could decrease
283     cumulative COVID-19 deaths by January 1st 2021 by 0.82 million deaths (95% UI 0.43 to 1.49 million).
284     This represents a 26.5% reduction in the number of deaths expected from August 28th to January 1st
285     2021. The benefits of increased mask use are greatest in settings with ongoing substantial transmission
286     and low current levels of mask use regardless of sociodemographic status. Our models also show that in
287     many settings, increased mask use will delay the need re-imposition of social distancing mandates by
288     many weeks or even months; in addition to the lives saved, a delay in re-imposition of social mandates
289     might also be accompanied by substantial economic benefits.
290     The estimate of 40% effectiveness of non-medical mask use by the general public is based on 13
291     observations (from 9 studies) specific to the general population, from a total of 63 observations from 40
292     separate studies included in the meta-regression. The uncertainty interval is wide, from 20% to 54%
293     reduction in transmission. Even with this uncertainty interval, there was absolutely no indication of any
                                                                          14

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
294     harmful impacts of mask use, such as tendencies for engaging in riskier behaviour or self-contamination
295     via more frequent face touching, as has been suggested.67,68 Further, the published studies of SARS-CoV-
296     2 included in our analysis of mask effectiveness demonstrated reductions in relative risk of 30% - 100%,
297     with the one study of non-medical mask use amongst the general population, indicating a reduction of
298     42% for any mask use and 70% for consistent mask use.69 Mask effectiveness is also supported by
299     additional evidence from laboratory studies that report on the efficacy of masks in reducing exhalation
300     of both aerosols and droplets by those infected with SARS CoV-2.70 Further, a recent case series
301     reported no secondary infections among 139 individuals exposed to two symptomatic hair stylists with
302     confirmed COVID-19 while both the stylists and their clients wore masks.71 In addition, a study of Swiss
303     soldiers indicated that physical distancing and use of medical masks led to no COVID-19 symptoms
304     despite the presence of virus-specific antibodies72, while a study of healthcare workers indicated that
305     universal use of medical masks was associated with lower rate of SARS-CoV-2 positive tests73. Based on
306     all types of available evidence, it seems critical to encourage mask use throughout the world as the
307     benefits can be substantial with low to zero contraindications. Guidance for specific materials, handling
308     of face coverings and other considerations is rapidly evolving as additional evidence emerges74.
309     At the population level, the regression analysis of the determinants of the transmission parameter
310     suggests a much larger effect of mask use than the one seen in the published studies. To avoid the risk
311     of over-stating the benefits of mask use in this analysis, however, we have constrained the regression to
312     yield results that are consistent with the range of the effect sizes found in the individual level studies. In
313     other words, the benefits of a universal mask use mandate could be substantially larger and what we
314     report here can be seen as a conservative estimate of the impact of mask use on lives saved.
315     Given that the cost of masks is very low, mask mandates and/or the promotion of mask use seems
316     prudent, as the risk of adopting these policies is minimal and the potential benefits very large. In
317     recognition of this, over the last few months we have seen the number of countries and territories with
                                                                          15

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
318     mask mandates in place increase substantially. Nevertheless, there remains reluctance to adopt mask
319     use and to impose mask mandates. In some settings, the current epidemiological context means that
320     mask wearing is not viewed as a necessary part of control, such as in Norway where the Norwegian
321     Institute of Public Health determined that, given their current low prevalence, â€œ200,000 people would
322     need to wear facemasks to prevent one new infection per week.â€75 In other settings however, despite
323     increasing cases, public sentiment towards mask wearing hinders universal utilization. Past messages
324     from some governments have not encouraged mask use and may have actually discouraged mask use.76â€“
325     78
           Early on, WHO stated â€œthe wide use of masks by healthy people in the community setting is not
326     supported by current evidence and carries uncertainties and critical risksâ€2 and only changed their official
327     position on June 5th to encourage mask use.79 This reluctance to embrace mask use given no real risks of
328     use and considerable potential health and economic benefits is hard to understand and justify. For those
329     decision-makers who are concerned with the economic effects of social distancing mandates, mask use
330     mandates provide a low-cost strategy to reduce the risk of a further round of social distancing mandates
331     and the associated unemployment and economic downturn.
332     While the effective R, the number of new infections created by a single infection under the auspices of
333     control, can potentially be reduced by one-third through universal mask use compared to no mask use,
334     mandates alone will likely be insufficient to control the epidemic in many locations. Even with universal
335     mask use, we expect the death toll due to COVID-19 to reach 2.18 million deaths by the end of the year,
336     and many more in 2021, assuming an efficacious vaccine is not discovered, licensed and widely deployed
337     in the interim. Countries will have to consider other policy strategies to reduce transmission, including
338     increasing testing, contact tracing, and isolation, along with â€œsmart mandatesâ€, which refers to targeting
339     mandates or restrictions to particular subgroups of the population, such as specific age-groups or local
340     communities for short periods of time. A central policy challenge for many countries is understanding
                                                                          16

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
341     which of these mandates targeting strategies makes the most sense in a given context and at what level
342     of COVID-19 transmission. This is the focus of our ongoing work.
343     The findings of this study should be interpreted while taking into account its limitations. First, there is a
344     set of limitations related to the meta-regression, including the following. The number of published
345     studies on the protection provided by cloth masks worn by the general public is limited. With rapid
346     development of the COVID-19 literature, new data on the effectiveness of masks can quickly be
347     incorporated into our meta-regression model. Future studies could change our pooled estimate of the
348     effect size and/or the large uncertainty interval around it in the meta-regression. As we looked at
349     multiple observations per study, it was not really feasible to account for all possible clustering. We
350     performed sensitivity analyses (shown in the Appendix) and found minimal differences in investigating
351     the role of clustering in our results. Studies had different endpoints and while we controlled for that in
352     our meta-regression, it would be ideal to have more studies that focus on COVID-19 as an endpoint.
353     Second, related to the modeling framework, we use an SEIR model to predict the course of the epidemic
354     with and without universal mask use. In general, SEIR models have tended to overestimate the
355     infections and deaths associated with COVID-19. Over-estimation is likely due to the fact that individuals
356     change their behaviours as the epidemic gets worse around them and governments tend to react when
357     hospital systems are nearing capacity. We have built the government response into our reference
358     scenario and have tried to use empirically observed data on mobility and current mask use to reflect the
359     individual behavioural response. Further, our model makes a number of simplifying assumptions
360     associated with mixing and transmission heterogeneity and as such, our conclusions must be considered
361     with these assumptions in mind. Also, we use a log-linear mixed regression which does not take into
362     account the potential for non-linear relationships We acknowledge that there are likely non-linear
363     relationships between some of the drivers of transmission and transmission intensity. Moreover, we
364     expect there to also be complex lagged relationships between covariates and transmission (e.g., fatigue
                                                                          17

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
365     related to duration of mandate altering its impact on transmission). Improving how our model uses
366     covariates to capture temporal variation in new infections is an open avenue of research.
367     Third, our out-of-sample predictive validity testing has shown that errors tend to progressively get larger
368     the longer the forecast, but has also shown that errors are much larger in settings where there are
369     fewer than 50 total deaths to date. For example, predictions from publicly available models for sub-
370     Saharan Africa have been particularly bad.66
371     Fourth, we assume cases and deaths are accurately reported by JHU except in Ecuador, Kazakhstan and
372     where excess mortality analyses have indicated substantial underreporting of COVID-19 deaths. Other
373     countries may not be detecting or reporting deaths and cases due to lack of testing or other
374     considerations. Overall, though, we believe that our prediction model performs well and where antibody
375     tests have been conducted at the population level, we have found our model based on deaths has
376     matched these results.64
377     Fifth, our models are sensitive to the trends in the last 7-14 days in deaths and somewhat sensitive to
378     the trend in cases. In settings where deaths and cases are steadily rising, the model will tend to have
379     large estimates of Î²t. If the rise in transmission is not captured by trends in mobility or other covariates,
380     the unexplained residual in the model increases and this is then reflected in the forecasts by day
381     through to January 1st. The reverse relationship also holds true for when there is a consistent downward
382     trend. The sensitivity of our model to data trends is a strength in that it makes our models reflect the
383     on-the-ground realities; it is also a challenge in the sense that our model results will change when there
384     are changes in recent transmission that are not captured by the covariates.
385     Sixth, we rely on self-reported data which is collected via mobile phone app-based surveys on use of
386     masks. In addition to the usual biases that accompany self-reported data, in this case we do not know
387     whether in settings with mask mandates in place, respondents may be reporting their behavior
                                                                          18

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
388     differently compared to settings without mask mandates. The respondents to app-based surveys are
389     also likely to not be a truly representative sample of the populations in each location. The degree to
390     which the respondents represent the general population varies across locations, and depends on the
391     prevalence of Facebook and other app use in each country. While this is a limitation of the data that are
392     currently available, we believe that given the samples tend to be biased towards more educated, urban,
393     and younger populations, the reported mask use is likely to be an over-estimate in these locations. If
394     this is true, then the estimates of the impact of expanding mask use to reach 95% coverage in these
395     populations would be an underestimate of the true effect of the intervention.
396     These limitations highlight important areas for improvement across the entire spectrum of research
397     related to COVID-19. There is a critical need for more and higher quality data across the spectrum of
398     information required to understand the trajectory of this pandemic, starting with better and higher-
399     quality information on the numbers of cases and deaths, to improved and more representative data on
400     use of masks among populations across the world, to additional studies that quantify the effect of face
401     coverings on transmission probability of SARS-COV2 among the general population, to better data on
402     social distancing mandates implemented in each location and the extent to which they are enforced. On
403     the modeling side, continued work on making modeling frameworks more flexible and including
404     alternative model specifications, as well as improving on how covariates are used to capture temporal
405     variation in new infections might lead to improvements in the performance of long-range forecasts. A
406     greater understanding of how the drivers of this pandemic interact with each other and affect
407     transmission probabilities is critical for influencing its trajectory over the next few months.
408     Conclusion
409     The COVID-19 epidemic is far from over. While a selection of therapeutics is showing promise, a vaccine
410     that can be deployed at global scale does not exist and is unlikely to be widely available in the near
                                                                          19

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
411     future. We expect more deaths in the second half of 2020 than were seen in the first six months. Not
412     only are there large epidemics unfolding in Latin America, the Middle-East and South Asia, but
413     seasonality suggests a second wave can be anticipated in the Northern Hemisphere. The rising toll of the
414     COVID-19 pandemic can be reduced by 0.82 million deaths in the next few months by the adoption of
415     universal mask mandates. This low-cost intervention that is available and accessible to all populations,
416     regardless of socio-economic status or other dimensions of inequity, has enormous health benefits and
417     might also lead to large economic benefits by delaying the need for re-imposition of social distancing
418     mandates. In global health we rarely encounter effective, low-cost, and universally available
419     interventions that can save lives: immediately, equitably and safely. Ensuring that individuals, as well as,
420     local, national and global decision makers are all doing everything in their power to achieve the highest
421     rates of mask use in all exposed populations is one of the best strategies available to us to mitigate the
422     toll of the pandemic in the months to come.
423
                                                                          20

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
424     Figures
425     Figure 1. Relative risk of viral respiratory infection among users of different types of facemasks.
426
427     This analysis includes only variables addressing facemask type (non-medical versus medical) and population type of
428     mask user (general population versus healthcare setting). The size of the box is proportional to the precision of the
429     estimate, based on number of observations, with more precise studies having larger boxes.
430
431
432
                                                                          21

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
433     Figure 2. Proportion of the population that self-report always wearing a facemask when outside the
434     home on July 21, 2020.
435
436
437
438
439
440
441
                                                                          22

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
442     Figure 3. Proportion of the population that self-report always wearing a facemask when outside the
443     home by Global Burden of Disease study super-region between March 1, 2020 and September 30,
444     2020. Values after the last date of observed survey data are dashed lines and horizontal projections
445     from the last observed values.
446
447
448
449
                                                                          23

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
450     Figure 4. Projected global deaths due to COVID-19 up to January 1, 2021 in the scenario for current
451     projections of mask use and the scenario with 95% coverage of mask use. Projections are shown for
452     the world and for the seven super-regions as defined in the Global Burden of Disease Study.
453
454
                                                                          24

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
455     Figure 5. Percent reduction in cumulative deaths on January 1, 2021 in the universal mask use
456     scenario and the reference scenario.
457
458
459     Areas have â€œno estimatesâ€ either because of no available data or because the population size, cases or deaths are
460     so small that the SEIR models do not run.
461
                                                                          25

Table 1. The difference in cumulative deaths between the universal mask use scenario and the reference (current mask use) scenario globally
and for each GBD super-region, region, country, and first administrative subnational on January 1, 2021.
 Location                                                                                                        Cumulative deaths in reference
                                                 Lives saved (95% UI)      Percent difference in deaths (95% UI)
                                                                                                                       scenario (95% UI)
 Global                                      815564 (430556 to 1490969)          -26.5% (-37.1 to -19.1%)        2996714 (2198771 to 4516689)
 Central Europe, Eastern Europe, and Central
 Asia                                         134421 (64565 to 280696)            -57.7% (-75 to -43.4%)           224915 (143896 to 388691)
  Central Asia                                  2408 (-2708 to 12197)              -6.8% (-29.1 to 10.3%)           30369 (16348 to 53472)
  Armenia                                         1010 (427 to 2641)             -39.3% (-57.9 to -25.7%)             2441 (1601 to 4671)
  Azerbaijan                                         54 (6 to 243)                 -7.8% (-29.2 to -1.1%)               620 (557 to 826)
  Georgia                                              0 (0 to 0)                      0% (-0.1 to 0%)                   17 (17 to 18)
  Kazakhstan                                    -3413 (-7647 to -923)                20% (7.2 to 45.3%)              17510 (7704 to 28212)
  Kyrgyzstan                                          6 (0 to 34)                     -0.6% (-3 to 0%)                1082 (1061 to 1126)
  Tajikistan                                          4 (0 to 35)                  -2.8% (-31.7 to -0.1%)                76 (70 to 111)
  Uzbekistan                                     4746 (912 to 14648)             -52.4% (-68.1 to -37.2%)            8622 (2248 to 24544)
  Central Europe                               33643 (12584 to 84666)             -55% (-77.7 to -35.8%)            57864 (31281 to 115111)
  Albania                                         1281 (191 to 3257)             -72.6% (-89.2 to -36.4%)             1649 (527 to 3673)
  Bosnia and Herzegovina                          1706 (283 to 3958)             -58.7% (-77.2 to -29.1%)             2717 (966 to 5302)
  Bulgaria                                       3255 (108 to 11390)             -69.5% (-91.3 to -14.4%)             4108 (760 to 12672)
  Croatia                                            80 (1 to 665)                -12.4% (-75.5 to -0.5%)               282 (189 to 881)
  Czechia                                          3784 (7 to 18324)              -69.9% (-97.3 to -1.6%)             4245 (439 to 18795)
  Hungary                                        1820 (158 to 10666)              -52.6% (-89 to -19.5%)              2614 (803 to 12065)
  Montenegro                                        299 (4 to 712)                -51.5% (-81.1 to -3.3%)              536 (107 to 1283)
  North Macedonia                                  843 (283 to 2577)             -48.9% (-73.1 to -29.4%)             1602 (957 to 3546)
  Poland                                       17603 (4428 to 53995)             -78.8% (-93.5 to -60.4%)            21056 (6870 to 58691)
  Romania                                        2460 (-594 to 5737)                -15% (-29.2 to 2.8%)             17537 (9418 to 28963)
  Serbia                                            188 (8 to 785)                -15.9% (-48.9 to -1.1%)              959 (758 to 1583)
  Slovakia                                             0 (0 to 0)                   -0.4% (-0.8 to -0.1%)                36 (34 to 39)
  Slovenia                                          324 (2 to 2580)               -34.7% (-83.9 to -1.6%)              524 (134 to 3298)
                                                                        26

Location                                                                                      Cumulative deaths in reference
                              Lives saved (95% UI)      Percent difference in deaths (95% UI)
                                                                                                    scenario (95% UI)
 Eastern Europe             98371 (49111 to 201686)            -70% (-83.9 to -56.6%)           136682 (84900 to 248375)
 Belarus                      4125 (362 to 18176)             -71.4% (-94.3 to -33.4%)            5011 (1083 to 19208)
 Estonia                          50 (1 to 387)                   -24% (-83.3 to -1%)                116 (64 to 462)
 Latvia                             0 (0 to 0)                     -0.1% (-0.3 to 0%)                 34 (33 to 35)
 Lithuania                          0 (0 to 0)                     -0.1% (-0.4 to 0%)                 84 (82 to 90)
 Republic of Moldova           1234 (541 to 2597)              -35% (-49.1 to -23.8%)              3440 (2024 to 6095)
 Russian Federation         68531 (34249 to 145960)           -71.3% (-85.7 to -57.4%)           93209 (59097 to 170351)
 Ukraine                     24431 (8090 to 56899)               -68% (-83 to -54.3%)            34789 (13634 to 73926)
High-income                250073 (108951 to 571964)           -24% (-40.2 to -15.1%)          995094 (712918 to 1660553)
 Australasia                    477 (65 to 1619)               -29.4% (-58.2 to -7.8%)             1387 (812 to 2788)
 Australia                      477 (65 to 1619)                -29.9% (-58.7 to -8%)              1364 (790 to 2766)
 New Zealand                        0 (0 to 0)                      0% (-0.1 to 0%)                   22 (22 to 23)
 High-income Asia Pacific    13358 (1388 to 36167)              -14.2% (-22.9 to -3%)            127298 (9560 to 506645)
 Japan                       13358 (1388 to 36167)              -14.4% (-23.6 to -3%)            126947 (9215 to 506285)
 Republic of Korea                  0 (0 to 1)                     -0.1% (-0.3 to 0%)                324 (316 to 337)
 Singapore                          0 (0 to 0)                        0% (0 to 0%)                    27 (27 to 27)
 High-income North America  96640 (60284 to 158525)           -23.6% (-34.1 to -16.3%)          404455 (348869 to 486600)
 Canada                       3145 (370 to 13910)              -15.5% (-37.5 to -3.6%)           16562 (10435 to 41631)
  Alberta                           1 (0 to 2)                   -0.3% (-0.8 to -0.1%)               256 (244 to 275)
  British Columbia                  0 (0 to 0)                     -0.1% (-0.2 to 0%)                203 (199 to 209)
  Manitoba                          0 (0 to 1)                    -1.4% (-3 to -0.3%)                 20 (15 to 27)
  Nova Scotia                      14 (0 to 93)                -10.7% (-48.8 to -0.7%)                84 (65 to 191)
  Ontario                       421 (69 to 2389)                -9.2% (-37.1 to -2.2%)             3666 (3078 to 6544)
  Quebec                      2710 (213 to 13540)              -17.4% (-40.7 to -3.2%)            12307 (6612 to 37237)
  Saskatchewan                      0 (0 to 0)                   -0.6% (-1.5 to -0.2%)                26 (24 to 31)
 United States of America   93495 (59329 to 150967)           -23.9% (-34.3 to -16.6%)          387893 (335888 to 465041)
  Alabama                      1178 (137 to 3210)              -28.4% (-51.9 to -5.9%)             3684 (2319 to 6213)
  Alaska                            1 (0 to 4)                   -1.1% (-8.1 to -0.2%)                37 (34 to 50)
                                                     27

Location                                                                             Cumulative deaths in reference
                       Lives saved (95% UI)    Percent difference in deaths (95% UI)
                                                                                          scenario (95% UI)
 Arizona                1723 (727 to 3349)            -19.2% (-29 to -10.6%)             8723 (6723 to 12227)
 Arkansas               1458 (116 to 3691)              -43.3% (-64 to -13%)              2999 (908 to 6138)
 California           18044 (7422 to 33622)          -32.6% (-44.2 to -21.9%)           54014 (32829 to 84006)
 Colorado               1049 (186 to 3797)              -27.3% (-59 to -8.4%)            3288 (2233 to 6371)
 Connecticut             255 (53 to 1102)              -4.9% (-18.7 to -1.2%)            4846 (4580 to 5853)
 Delaware                 138 (14 to 577)             -14.6% (-42.4 to -2.2%)             793 (628 to 1324)
 District of Columbia     271 (60 to 745)             -21.9% (-39.6 to -8.1%)             1119 (740 to 2084)
 Florida              -1116 (-5457 to 1416)              4.1% (-4.6 to 17.8%)           26485 (16989 to 39801)
 Georgia               3126 (1373 to 5395)           -22.4% (-31.8 to -13.6%)           13769 (8994 to 20009)
 Hawaii                      4 (0 to 8)                 -1.7% (-9.2 to -0.3%)                66 (51 to 91)
 Idaho                   757 (157 to 1922)           -42.9% (-59.4 to -23.8%)             1670 (636 to 3542)
 Illinois             6912 (2353 to 17123)            -37% (-58.2 to -20.2%)            17496 (11463 to 30332)
 Indiana               3571 (1580 to 8283)           -42.2% (-61.5 to -28.2%)            8059 (5578 to 13589)
 Iowa                   1158 (406 to 2576)           -31.2% (-45.4 to -18.9%)            3580 (1985 to 6780)
 Kansas                 1386 (408 to 3868)           -63.9% (-84.1 to -42.6%)             2027 (960 to 4656)
 Kentucky               1284 (385 to 2965)           -29.8% (-43.5 to -16.8%)            4299 (1857 to 10252)
 Louisiana              2029 (886 to 3158)           -22.3% (-29.9 to -13.1%)            8946 (6638 to 11541)
 Maine                    109 (11 to 618)               -30% (-75.7 to -7.6%)              263 (147 to 811)
 Maryland               1383 (540 to 2822)           -23.7% (-39.5 to -11.8%)            5626 (4566 to 7222)
 Massachusetts         2725 (1096 to 6933)            -18.9% (-35.5 to -9.5%)           13788 (11213 to 19579)
 Michigan             4550 (1465 to 12387)            -33% (-57.2 to -16.3%)            12758 (8938 to 21972)
 Minnesota             2479 (1052 to 5096)           -40.6% (-56.3 to -26.4%)            5888 (3796 to 9798)
 Mississippi            1420 (527 to 2386)           -28.3% (-38.6 to -15.5%)            4869 (3372 to 6526)
 Missouri               2357 (381 to 6592)           -36.4% (-53.7 to -16.1%)            6020 (2281 to 16923)
 Montana                     1 (0 to 8)                 -1.2% (-6.5 to -0.2%)               107 (96 to 130)
 Nebraska               1081 (446 to 2533)            -61% (-79.5 to -44.1%)              1693 (965 to 3241)
 Nevada                 643 (-150 to 1451)             -14.6% (-26.9 to 2.8%)            4479 (2301 to 7272)
 New Hampshire            186 (28 to 659)             -23.9% (-55.4 to -5.8%)             674 (482 to 1230)
                                            28

Location                                                                                  Cumulative deaths in reference
                           Lives saved (95% UI)     Percent difference in deaths (95% UI)
                                                                                                scenario (95% UI)
  New Jersey                 407 (80 to 1521)                -2.4% (-8.3 to -0.5%)           16730 (16199 to 18212)
  New Mexico                1369 (570 to 2896)            -51.2% (-67.9 to -35.6%)             2577 (1602 to 4385)
  New York                  1913 (311 to 6275)              -5.2% (-15.5 to -0.9%)           35560 (33519 to 40959)
  North Carolina           5472 (1544 to 11963)           -49.9% (-67.3 to -30.3%)            10415 (4927 to 18600)
  North Dakota               355 (169 to 733)             -55.1% (-70.8 to -41.4%)              621 (400 to 1055)
  Ohio                     5620 (2206 to 13363)           -47.1% (-68.1 to -30.4%)            11347 (7296 to 20017)
  Oklahoma                  1665 (580 to 3646)            -43.6% (-57.7 to -29.9%)             3714 (1794 to 7090)
  Oregon                    2267 (550 to 6464)             -68.1% (-85.7 to -47%)              3119 (1173 to 7598)
  Pennsylvania             6137 (1732 to 19494)           -30.8% (-50.7 to -15.4%)           18168 (11151 to 38785)
  Rhode Island               421 (73 to 1592)              -20.5% (-45.1 to -6.1%)             1755 (1194 to 3735)
  South Carolina            2279 (905 to 4332)            -34.3% (-46.8 to -21.1%)             6426 (4269 to 9660)
  South Dakota                240 (63 to 567)             -48.3% (-69.5 to -24.5%)               463 (256 to 829)
  Tennessee                 1991 (777 to 3818)            -29.1% (-38.9 to -20.1%)            6757 (3342 to 12108)
  Texas                   -5057 (-11946 to -860)              16.6% (3 to 38.8%)             30644 (21885 to 40804)
  Utah                      1370 (414 to 3312)            -64.5% (-83.1 to -44.9%)             1998 (916 to 4211)
  Vermont                       3 (0 to 21)                   -4.1% (-25.4 to 0%)                 62 (58 to 83)
  Virginia                   780 (28 to 2603)              -17.3% (-41.5 to -1.1%)             3777 (2574 to 6416)
  Washington               3164 (1216 to 6444)            -44.7% (-61.2 to -30.3%)            6863 (3864 to 12327)
  West Virginia               282 (43 to 890)             -41.3% (-69.4 to -15.4%)              584 (279 to 1315)
  Wisconsin                 2658 (480 to 7754)            -56.9% (-81.4 to -27.3%)             4213 (1747 to 9555)
  Wyoming                        0 (0 to 0)                  -0.3% (-0.5 to -0.2%)                34 (32 to 36)
 Southern Latin America     2096 (885 to 3789)               -5.2% (-7.9 to -2.9%)           39535 (29734 to 49870)
 Argentina                  1998 (798 to 3724)              -7.8% (-11.1 to -4.9%)           24972 (15882 to 35043)
 Chile                        98 (46 to 194)                 -0.7% (-1.2 to -0.3%)           14513 (12932 to 16643)
 Uruguay                         0 (0 to 0)                  -0.2% (-0.6 to -0.1%)                50 (46 to 58)
 Western Europe         137502 (34764 to 400664)          -29.1% (-52.4 to -12.9%)          422419 (265320 to 786956)
 Andorra                       32 (1 to 160)                -24% (-62.2 to -2.2%)                 97 (56 to 270)
 Austria                   4262 (523 to 22283)            -70.9% (-95.5 to -39.6%)            5130 (1303 to 23275)
                                                 29

Location                                                                                 Cumulative deaths in reference
                          Lives saved (95% UI)     Percent difference in deaths (95% UI)
                                                                                              scenario (95% UI)
 Belgium                   2951 (420 to 9818)              -12.3% (-25 to -3.4%)            21299 (12103 to 53485)
 Cyprus                         0 (0 to 0)                   -0.1% (-0.2 to 0%)                  21 (20 to 21)
 Denmark                    844 (111 to 4271)            -42.9% (-85.9 to -14.3%)             1530 (777 to 4973)
 Finland                   2488 (52 to 15439)            -62.8% (-97.6 to -13.2%)            2846 (393 to 15840)
 France                  26193 (4775 to 123424)          -29.7% (-61.9 to -11.4%)          72074 (41454 to 207948)
 Germany                 35016 (5447 to 133085)          -58.5% (-83.8 to -31.8%)          52402 (16961 to 176009)
  Baden-Wurttemberg       4735 (215 to 32693)              -40.6% (-88 to -9.5%)             7278 (2266 to 37786)
  Bavaria                 7705 (287 to 52186)             -38.7% (-73.6 to -8.6%)           14073 (3300 to 77704)
  Berlin                    1293 (2 to 13290)             -34.9% (-94.4 to -0.8%)            1596 (226 to 13983)
  Brandenburg                 96 (5 to 490)                -25.4% (-72.4 to -3%)               271 (174 to 677)
  Bremen                      40 (0 to 299)               -21.3% (-81.6 to -0.8%)                98 (56 to 372)
  Hamburg                   1183 (63 to 4921)            -39.2% (-63.2 to -14.4%)            2789 (409 to 13787)
  Hesse                     674 (63 to 3228)             -41.5% (-82.6 to -10.4%)             1255 (603 to 3847)
  Lower Saxony              377 (20 to 2420)              -23.5% (-73.8 to -2.9%)             1071 (681 to 3279)
  Mecklenburg-Vorpommern        0 (0 to 0)                      0% (0 to 0%)                     20 (20 to 20)
  North Rhine-Westphalia 12592 (1985 to 52956)           -70.4% (-92.1 to -45.2%)           15781 (4319 to 57544)
  Rhineland-Palatinate     2175 (65 to 16503)            -61.9% (-94.2 to -19.9%)            2588 (323 to 17724)
  Saarland                   434 (3 to 4258)              -28.1% (-75.4 to -1.4%)             796 (188 to 6016)
  Saxony                    2119 (2 to 19528)              -43.8% (-93 to -1.1%)             2642 (228 to 21613)
  Saxony-Anhalt                 0 (0 to 0)                   -0.1% (-0.1 to 0%)                  65 (64 to 66)
  Schleswig-Holstein         581 (2 to 3027)              -55.3% (-91.3 to -0.9%)             781 (161 to 3315)
  Thuringia                 1013 (15 to 8697)             -49.5% (-92.3 to -7.2%)             1299 (209 to 9388)
 Greece                      307 (7 to 1523)              -33.2% (-81.7 to -2.3%)             615 (292 to 1859)
 Iceland                        0 (0 to 0)                      0% (0 to 0%)                     11 (11 to 11)
 Ireland                    442 (114 to 1583)             -15.5% (-41.2 to -5.5%)            2502 (2073 to 3889)
 Israel                     318 (-424 to 911)              -4.8% (-11.5 to 4.6%)             7259 (4198 to 12909)
 Italy                   11414 (2840 to 43608)            -18.8% (-46.2 to -6.8%)           53593 (41492 to 93274)
  Abruzzo                     29 (6 to 103)                 -5% (-15.6 to -1.2%)               548 (507 to 656)
                                                30

Location                                                                                       Cumulative deaths in reference
                                 Lives saved (95% UI)    Percent difference in deaths (95% UI)
                                                                                                    scenario (95% UI)
  Basilicata                           0 (0 to 0)                      0% (0 to 0%)                    28 (28 to 28)
  Calabria                            12 (0 to 54)               -9.3% (-35.3 to -0.4%)               109 (96 to 153)
  Campania                          180 (3 to 1109)             -17.7% (-67.4 to -0.6%)             643 (442 to 1626)
  Emilia-Romagna                   524 (183 to 1545)             -9.3% (-23.4 to -3.7%)            5379 (4934 to 6581)
  Friuli-Venezia Giulia             452 (9 to 3052)             -22.4% (-52.6 to -2.4%)             1348 (388 to 7194)
  Lazio                          2157 (213 to 12406)           -38.9% (-68.1 to -15.4%)            4301 (1374 to 20065)
  Liguria                           184 (69 to 567)                -9.3% (-24 to -3.9%)            1903 (1750 to 2406)
  Lombardia                       1630 (312 to 7450)             -7.3% (-27.8 to -1.8%)           19525 (17681 to 26987)
  Marche                           400 (33 to 1999)             -13.4% (-32.4 to -2.8%)            2357 (1153 to 8319)
  Molise                             24 (0 to 178)               -25.6% (-83 to -1.3%)                 49 (24 to 206)
  Piemonte                         743 (215 to 2604)            -12.7% (-34.3 to -4.6%)            5319 (4656 to 7605)
  Provincia autonoma di Bolzano    451 (28 to 1549)             -29.9% (-51.5 to -7.6%)             1294 (368 to 4953)
  Provincia autonoma di Trento     201 (15 to 1306)              -20% (-63.7 to -3.3%)              693 (449 to 2007)
  Puglia                            60 (17 to 159)               -8.5% (-19.7 to -2.8%)              680 (617 to 810)
  Sardegna                          171 (1 to 1246)              -23% (-84.7 to -0.5%)              320 (134 to 1444)
  Sicilia                         2513 (32 to 23857)            -55.5% (-92.5 to -9.8%)            3053 (326 to 25558)
  Toscana                           188 (42 to 833)             -11.3% (-37.6 to -3.3%)            1452 (1254 to 2215)
  Umbria                             59 (1 to 431)                 -20.9% (-77 to -1%)                146 (80 to 564)
  Valle d'Aosta                      10 (-17 to 46)               -4.6% (-13.9 to 3.6%)              232 (160 to 541)
  Veneto                          1424 (438 to 4813)           -30.2% (-59.1 to -14.5%)            4214 (3018 to 8085)
 Luxembourg                         222 (2 to 1798)             -32.2% (-79.7 to -1.5%)             410 (131 to 2217)
 Malta                                 0 (0 to 0)                   -0.2% (-0.7 to 0%)                 11 (10 to 12)
 Netherlands                    23283 (2449 to 70697)           -55.2% (-77 to -23.8%)           37734 (10128 to 112518)
 Norway                                1 (0 to 3)                 -0.3% (-0.9 to -0.1%)              273 (269 to 283)
 Portugal                        4040 (842 to 16130)           -40.6% (-63.7 to -22.2%)            8625 (3616 to 26575)
 San Marino                            2 (1 to 6)                  -4% (-12.5 to -1.3%)                46 (44 to 51)
 Spain                            2172 (842 to 4217)                 -3.4% (-5 to -2%)           62759 (40401 to 114006)
  Andalucia                         233 (9 to 943)                -3.2% (-7.3 to -0.5%)            7248 (1728 to 30953)
                                                      31

Location                                                                                          Cumulative deaths in reference
                                   Lives saved (95% UI)     Percent difference in deaths (95% UI)
                                                                                                        scenario (95% UI)
  Aragon                              304 (32 to 568)                -8.7% (-13.5 to -2%)              3309 (1515 to 5909)
  Asturias                             108 (3 to 357)               -6.1% (-13.1 to -0.8%)             1622 (368 to 6480)
  Balearic Islands                     41 (0 to 237)                -3.5% (-10.3 to -0.1%)              820 (242 to 5117)
  Basque Country                       62 (10 to 177)                -1.8% (-3.8 to -0.5%)             3233 (1888 to 7052)
  Canary Islands                       88 (1 to 672)               -10.8% (-32.6 to -0.6%)              456 (182 to 2132)
  Cantabria                             3 (-14 to 20)                 -0.8% (-2.6 to 1.4%)              526 (260 to 1404)
  Castile and Leon                     49 (-8 to 137)                 -1.3% (-2.9 to 0.2%)             3825 (2493 to 7854)
  Castilla-La Mancha                   76 (11 to 238)                -1.5% (-3.6 to -0.3%)             4438 (3274 to 9137)
  Catalonia                           140 (-16 to 556)                -1.3% (-3.7 to 0.1%)            10137 (6343 to 29466)
  Community of Madrid                543 (114 to 1101)                 -3.3% (-5.5 to -1%)           15711 (11045 to 25243)
  Extremadura                         139 (22 to 305)               -7.2% (-11.1 to -2.8%)             1840 (735 to 5117)
  Galicia                             289 (18 to 562)                -5.4% (-8.6 to -1.2%)             6021 (895 to 16290)
  La Rioja                              42 (3 to 90)                 -4.4% (-8.3 to -0.7%)              876 (399 to 2053)
  Murcia                               24 (1 to 287)                -3.7% (-22.4 to -0.3%)              255 (162 to 1135)
  Navarre                              24 (2 to 113)                 -2.2% (-6.2 to -0.3%)              883 (574 to 2814)
  Valencian Community                    7 (1 to 22)                 -0.4% (-1.3 to -0.1%)             1558 (1514 to 1642)
 Sweden                            5877 (723 to 33748)            -34.7% (-80.9 to -10.3%)            12630 (7010 to 43042)
 Switzerland                       6062 (523 to 29072)             -55.7% (-91 to -19.4%)             8494 (2693 to 32047)
 United Kingdom                   11576 (2407 to 41847)             -14.4% (-39.2 to -4%)            72058 (59867 to 109943)
  England                          6788 (836 to 32436)             -10.5% (-38.5 to -1.7%)           57268 (50309 to 83352)
  Northern Ireland                   513 (14 to 2526)               -18% (-48.9 to -1.6%)              2035 (899 to 8106)
  Scotland                         2183 (114 to 10057)             -20.5% (-51.4 to -2.6%)            7953 (4417 to 23462)
  Wales                             2093 (423 to 9185)            -36.5% (-74.8 to -13.8%)            4803 (3051 to 12082)
Latin America and Caribbean       37504 (25393 to 53623)               -7.2% (-9.9 to -5%)          516699 (480313 to 573553)
 Andean Latin America                770 (551 to 979)                  -1% (-1.3 to -0.8%)           74343 (71361 to 77374)
 Bolivia (Plurinational State of)    300 (147 to 463)                -4.2% (-5.8 to -2.4%)             7029 (6055 to 8255)
 Ecuador                             296 (217 to 367)                  -1.4% (-1.7 to -1%)           21830 (20856 to 22758)
 Peru                                174 (108 to 258)                -0.4% (-0.6 to -0.2%)           45484 (43143 to 47828)
                                                         32

Location                                                                                      Cumulative deaths in reference
                               Lives saved (95% UI)     Percent difference in deaths (95% UI)
                                                                                                    scenario (95% UI)
 Caribbean                      2837 (224 to 8748)             -15.2% (-37.7 to -1.9%)            16272 (7722 to 30615)
 Bahamas                            3 (0 to 31)                  -2% (-12.5 to -0.1%)                 83 (42 to 254)
 Barbados                            0 (0 to 0)                       0% (0 to 0%)                      8 (8 to 8)
 Belize                             8 (0 to 62)                 -4.1% (-37.3 to -0.1%)               107 (12 to 769)
 Cuba                                0 (0 to 0)                       0% (0 to 0%)                    91 (89 to 94)
 Dominican Republic               162 (-30 to 356)                -2.2% (-4.4 to 0.3%)            8068 (3761 to 14541)
 Guyana                             20 (0 to 85)                  -5.6% (-22.2 to 0%)                263 (35 to 1350)
 Haiti                           2536 (9 to 8390)               -65.3% (-91 to -4.3%)              3315 (222 to 11298)
 Jamaica                           43 (0 to 441)                  -3.7% (-33.6 to 0%)                324 (17 to 3744)
 Puerto Rico                       52 (13 to 91)                 -1.6% (-2.5 to -0.9%)             3448 (912 to 7194)
 Suriname                           4 (-9 to 10)                  -1.3% (-4.1 to 1.1%)               458 (147 to 961)
 Trinidad and Tobago                3 (0 to 35)                   -1.3% (-14.7 to 0%)                 40 (21 to 115)
 United States Virgin Islands       5 (0 to 22)                   -6.7% (-15.8 to 0%)                 68 (11 to 350)
 Central Latin America        10228 (4278 to 20014)              -4.4% (-8.1 to -1.8%)          230480 (200713 to 277348)
 Colombia                     -5432 (-9115 to -3011)             10.8% (6.6 to 16.9%)            50114 (41136 to 59430)
 Costa Rica                       213 (80 to 405)               -6.8% (-12.4 to -1.8%)             3573 (1229 to 7714)
 El Salvador                     296 (104 to 620)                -8.2% (-14 to -4.1%)              3756 (1438 to 8258)
 Guatemala                       365 (139 to 737)                -4.7% (-7.3 to -2.8%)            7500 (4493 to 11832)
 Honduras                         339 (6 to 1100)               -8.8% (-19.9 to -0.3%)             3250 (1719 to 6566)
 Mexico                       11813 (7537 to 17383)             -8.2% (-12.1 to -5.5%)          143326 (126904 to 163923)
  Aguascalientes                 249 (165 to 378)             -17.5% (-28.5 to -10.3%)             1454 (988 to 1854)
  Baja California                 136 (24 to 243)                -2.4% (-4.3 to -0.4%)             5688 (4567 to 6842)
  Baja California Sur              59 (17 to 96)                 -7.8% (-12 to -3.4%)               751 (445 to 1111)
  Campeche                         50 (19 to 79)                 -3.5% (-5.4 to -1.9%)             1422 (926 to 1822)
  Chiapas                         201 (40 to 688)              -12.1% (-29.9 to -3.5%)             1461 (1128 to 2388)
  Chihuahua                      114 (-101 to 280)                -3.6% (-8.3 to 2.2%)             3412 (2089 to 4950)
  Coahuila                        -22 (-210 to 90)                 0.4% (-3 to 4.9%)               3547 (2010 to 4973)
  Colima                          123 (60 to 177)              -11.8% (-17.2 to -7.6%)             1058 (626 to 1485)
                                                     33

Location                                                                                            Cumulative deaths in reference
                                     Lives saved (95% UI)     Percent difference in deaths (95% UI)
                                                                                                          scenario (95% UI)
  Durango                                368 (20 to 814)             -24.4% (-38.1 to -4.4%)             1384 (464 to 2828)
  Guanajuato                           1292 (79 to 2490)             -21.5% (-35.7 to -4.3%)            5806 (1819 to 11217)
  Guerrero                              332 (101 to 624)                -8% (-13.9 to -1.9%)             4258 (2848 to 6945)
  Hidalgo                              -303 (-688 to -54)               7.9% (1.3 to 17.8%)              3839 (2994 to 4716)
  Jalisco                             1164 (480 to 1915)             -15.2% (-23.1 to -9.2%)            7685 (4015 to 12106)
  Mexico                             3193 (1835 to 4891)            -16.6% (-22.9 to -11.8%)           19063 (14149 to 25313)
  Mexico City                          253 (-188 to 556)                 -1.5% (-3.4 to 1%)            17385 (15277 to 20112)
  Michoacan de Ocampo                    255 (66 to 447)              -5.8% (-10.3 to -1.1%)             4615 (2838 to 6901)
  Morelos                               -101 (-391 to 72)              4.3% (-2.6 to 14.8%)              2367 (1417 to 3828)
  Nayarit                                 96 (-9 to 203)               -6.3% (-12.4 to 0.6%)             1540 (935 to 2272)
  Nuevo Leon                            -19 (-239 to 142)                0.2% (-2.4 to 3.3%)             6202 (3850 to 8277)
  Oaxaca                                585 (316 to 907)             -14.8% (-21.5 to -9.5%)             3961 (2524 to 5680)
  Puebla                                580 (315 to 895)              -7.2% (-11.2 to -3.8%)            8202 (5675 to 10584)
  Queretaro                              115 (7 to 222)               -5.4% (-10.1 to -0.3%)             2212 (1251 to 3357)
  Quintana Roo                            -1 (-59 to 37)                  0% (-1.4 to 2.1%)              2776 (2413 to 3213)
  San Luis Potosi                       117 (-59 to 254)                -4.1% (-8.5 to 1.4%)             3152 (1543 to 4610)
  Sinaloa                               464 (105 to 906)             -10.7% (-17.5 to -3.4%)             4158 (3082 to 5636)
  Sonora                                 113 (3 to 434)               -3.4% (-10.5 to -0.1%)             2987 (2551 to 4237)
  Tabasco                               196 (134 to 268)                 -5% (-6.6 to -3.6%)             3915 (3461 to 4405)
  Tamaulipas                             168 (18 to 354)               -4.3% (-9.3 to -0.7%)             4159 (2110 to 6819)
  Tlaxcala                              212 (124 to 322)             -12.5% (-17.6 to -8.4%)             1691 (1302 to 2129)
  Veracruz de Ignacio de la Llave     1436 (672 to 2519)            -15.9% (-22.6 to -10.5%)            8908 (6002 to 12896)
  Yucatan                                 15 (-24 to 42)                -0.5% (-1.5 to 0.7%)             2971 (2018 to 3895)
  Zacatecas                              372 (66 to 787)            -26.9% (-40.9 to -11.1%)             1297 (605 to 2307)
 Nicaragua                             753 (187 to 2822)            -59.5% (-81.5 to -39.6%)             1156 (419 to 3664)
 Panama                                  80 (44 to 132)                  -1.7% (-2.7 to -1%)             4642 (3566 to 5919)
 Venezuela (Bolivarian Republic of)   1802 (306 to 4744)             -14.5% (-22.7 to -8.8%)            13163 (2198 to 42916)
 Tropical Latin America             23670 (16514 to 32318)           -12.1% (-15.1 to -9.1%)          195605 (177261 to 216305)
                                                           34

Location                                                                             Cumulative deaths in reference
                      Lives saved (95% UI)     Percent difference in deaths (95% UI)
                                                                                           scenario (95% UI)
 Brazil              22980 (16107 to 31013)           -11.9% (-14.9 to -9.1%)          192567 (172939 to 213949)
 Acre                      30 (9 to 59)                  -4% (-7.1 to -1.4%)                729 (656 to 830)
 Alagoas                 143 (82 to 216)                 -6% (-8.4 to -3.8%)              2355 (2179 to 2569)
 Amapa                   70 (26 to 126)                -8.4% (-13.7 to -3.6%)               819 (719 to 932)
 Amazonas               689 (277 to 1344)             -12.5% (-20.5 to -6.4%)             5340 (4291 to 6750)
 Bahia                3701 (2163 to 5740)             -23.1% (-30.5 to -16%)            15826 (12202 to 20682)
 Ceara                   252 (86 to 578)                 -2.6% (-5.6 to -1%)             9386 (8799 to 10382)
 Distrito Federal        85 (56 to 126)                  -2.2% (-3 to -1.6%)              3872 (3330 to 4509)
 Espirito Santo         513 (326 to 772)              -10.9% (-14.5 to -7.9%)             4659 (4059 to 5429)
 Goias                 1054 (300 to 1712)              -15% (-21.3 to -7.7%)             6888 (3846 to 10016)
 Maranhao                120 (60 to 223)                -3.1% (-5.3 to -1.6%)             3870 (3685 to 4137)
 Mato Grosso            208 (110 to 330)                -5.6% (-7.9 to -3.4%)             3656 (3217 to 4392)
 Mato Grosso do Sul     379 (197 to 600)                -19% (-25 to -13.1%)              1971 (1444 to 2668)
 Minas Gerais         4156 (1787 to 7668)            -26.3% (-35.1 to -17.5%)            15470 (9735 to 23790)
 Para                    306 (59 to 889)               -4.2% (-10.9 to -0.9%)             7002 (6314 to 8226)
 Paraiba                473 (267 to 887)              -11.7% (-17.8 to -8.1%)             3975 (3313 to 5110)
 Parana                 711 (269 to 1448)              -12% (-18.3 to -6.1%)              5686 (4357 to 8096)
 Pernambuco            1081 (575 to 1983)             -10.3% (-16.3 to -6.2%)            10358 (9119 to 12465)
 Piaui                   212 (76 to 372)                -8.4% (-13 to -3.7%)              2451 (2064 to 2919)
 Rio de Janeiro        2573 (566 to 5619)              -10% (-17.6 to -3.3%)            24472 (17382 to 34146)
 Rio Grande do Norte     163 (17 to 444)               -5.7% (-12.7 to -0.7%)             2701 (2264 to 3492)
 Rio Grande do Sul     1071 (255 to 2297)              -15.6% (-24.9 to -6%)              6485 (4277 to 9733)
 Rondonia                82 (33 to 156)                 -5.5% (-9.2 to -2.6%)             1453 (1257 to 1769)
 Roraima                   35 (7 to 65)                 -4.9% (-8.3 to -1.2%)               707 (625 to 804)
 Santa Catarina         835 (210 to 1788)             -16.1% (-25.5 to -6.8%)             4887 (3075 to 7767)
 Sao Paulo            3721 (1565 to 6722)              -8.3% (-12.8 to -4.4%)           43949 (35894 to 56669)
 Sergipe                 78 (36 to 123)                  -3.4% (-5 to -1.8%)              2238 (2051 to 2500)
 Tocantins               240 (95 to 385)             -17.3% (-22.7 to -10.6%)             1365 (886 to 1885)
                                            35

Location                                                                                        Cumulative deaths in reference
                                Lives saved (95% UI)      Percent difference in deaths (95% UI)
                                                                                                      scenario (95% UI)
 Paraguay                         690 (149 to 1616)             -23.1% (-34.5 to -13.5%)             3038 (902 to 8437)
North Africa and Middle East 124534 (70240 to 225566)           -48.1% (-60.5 to -37.6%)          253851 (177663 to 398457)
 Afghanistan                    4415 (125 to 21891)              -45.9% (-86.8 to -7.8%)            6643 (1596 to 29983)
 Algeria                       11791 (3936 to 30808)            -78.4% (-92.2 to -61.9%)            14313 (6230 to 33896)
 Bahrain                          369 (149 to 806)              -52.4% (-70.9 to -35.3%)              672 (411 to 1193)
 Egypt                         4910 (1868 to 16575)             -41.5% (-72.4 to -24.5%)            10803 (7569 to 22541)
 Iran (Islamic Republic of)   35201 (20644 to 63386)            -49.2% (-62.4 to -37.7%)           70238 (52788 to 103293)
 Iraq                          15293 (9647 to 22648)             -46.9% (-57.7 to -37%)            32454 (24889 to 45236)
 Jordan                            448 (0 to 9494)                  -6.7% (-98.3 to 0%)                497 (12 to 9530)
 Kuwait                           354 (107 to 801)              -29.8% (-47.4 to -14.3%)             1117 (732 to 1763)
 Lebanon                           221 (20 to 733)               -38.8% (-69.7 to -8.9%)              471 (222 to 1095)
 Libya                          3678 (1320 to 6985)              -76.7% (-88 to -62.5%)              4789 (1753 to 9222)
 Morocco                        4642 (-1692 to 9591)               -21.1% (-39.4 to 4%)            25438 (11257 to 46725)
 Oman                             501 (332 to 748)               -15.8% (-26.2 to -8.1%)             3302 (2035 to 4788)
 Palestine                       1853 (820 to 3022)             -61.2% (-81.2 to -29.2%)             3225 (1219 to 6136)
 Qatar                             302 (0 to 1205)                 -24.9% (-62.3 to 0%)               716 (196 to 2324)
 Saudi Arabia                  7691 (4241 to 12879)             -38.6% (-50.7 to -28.2%)           19591 (14083 to 27591)
 Sudan                          3444 (717 to 11761)              -69.8% (-92 to -43.9%)             4448 (1653 to 12853)
 Syrian Arab Republic           1455 (-1737 to 4381)              -28.4% (-57.5 to 8.8%)            8355 (1003 to 28240)
 Tunisia                          3547 (6 to 24378)              -70.5% (-98.8 to -6.2%)             3729 (105 to 24591)
 Turkey                        23128 (7823 to 57393)            -56.9% (-75.8 to -38.7%)           37993 (19853 to 78767)
 United Arab Emirates            1005 (250 to 2349)             -27.2% (-44.4 to -10.3%)            4152 (1070 to 11276)
 Yemen                            288 (27 to 1383)               -24.8% (-67.8 to -4.4%)              906 (617 to 2041)
South Asia                   216549 (100735 to 392702)           -27% (-35.8 to -18.9%)          794413 (484774 to 1325944)
 Bangladesh                   43206 (14774 to 98187)            -71.1% (-83.9 to -55.3%)           58297 (25558 to 121943)
 India                       158832 (75152 to 282838)           -22.5% (-30.7 to -14.9%)         703364 (431127 to 1173219)
  Andhra Pradesh                2379 (-1672 to 4927)               -7.2% (-16.2 to 3.4%)           36635 (23600 to 54621)
  Arunachal Pradesh                300 (0 to 1325)               -40.6% (-98.9 to -0.4%)               492 (8 to 1735)
                                                       36

Location                                                                                    Cumulative deaths in reference
                             Lives saved (95% UI)     Percent difference in deaths (95% UI)
                                                                                                 scenario (95% UI)
 Assam                       5248 (2212 to 9030)             -30.9% (-49.5 to -8.3%)           19529 (6619 to 37744)
 Bihar                      24344 (1648 to 74027)           -72.4% (-87.6 to -54.8%)           32362 (2913 to 100770)
 Chhattisgarh                 2538 (213 to 4418)             -17.3% (-33.6 to -0.7%)           18305 (6076 to 34827)
 Delhi                        2299 (945 to 5317)             -25.7% (-40.3 to -15%)             8522 (6051 to 14860)
 Goa                           297 (199 to 390)              -19.5% (-28 to -10.4%)             1563 (1061 to 2029)
 Gujarat                     5945 (1814 to 17281)           -41.5% (-60.9 to -25.6%)           13314 (6658 to 29470)
 Haryana                     5260 (2419 to 9633)             -35.8% (-49 to -21.7%)            15107 (7050 to 28373)
 Himachal Pradesh              1635 (44 to 6071)             -60% (-80.3 to -31.3%)             2581 (140 to 10776)
 Jammu & Kashmir and Ladakh  3392 (1796 to 5393)             -43.8% (-58.6 to -32%)             7782 (4469 to 12519)
 Jharkhand                   3878 (1597 to 6240)             -23.3% (-40.3 to -5.5%)           19114 (5975 to 34217)
 Karnataka                    107 (-4501 to 2826)                -0.7% (-7.3 to 8%)            45119 (27297 to 68596)
 Kerala                        1351 (97 to 2712)               -8.2% (-15 to -0.2%)            21021 (6293 to 50017)
 Madhya Pradesh             22319 (6449 to 47305)           -58.7% (-73.5 to -46.4%)           37537 (12689 to 83736)
 Maharashtra                  143 (-6264 to 4200)               -0.4% (-4.9 to 5.2%)          100542 (77736 to 129249)
 Manipur                       933 (234 to 1745)             -43.5% (-78.5 to -5.1%)             2621 (723 to 4765)
 Meghalaya                      168 (0 to 1078)               -8.1% (-58.1 to -0.1%)               771 (8 to 3612)
 Nagaland                          0 (0 to 0)                  -0.2% (-0.4 to -0.1%)                  8 (8 to 9)
 Odisha                      5463 (2020 to 9416)              -23.3% (-38 to -4.2%)            27328 (9552 to 54951)
 Punjab                       1386 (-913 to 2787)                -7.5% (-17 to 3%)             21415 (11810 to 33224)
 Rajasthan                  12962 (3658 to 35725)           -66.1% (-81.3 to -49.4%)           18581 (6866 to 46819)
 Tamil Nadu                  8089 (2076 to 15881)            -14.4% (-24.6 to -2.6%)           59039 (31558 to 98024)
 Telangana                   3694 (666 to 11479)            -52.9% (-73.2 to -32.5%)            6405 (1913 to 16536)
 Tripura                       815 (485 to 1121)             -23.7% (-43.1 to -9.4%)            3733 (2188 to 5269)
 Uttar Pradesh              36143 (16879 to 62750)          -33.1% (-47.5 to -14.3%)          116309 (48420 to 215109)
 Uttarakhand                   720 (60 to 1329)              -14.3% (-32.3 to -0.6%)            6737 (986 to 13967)
 West Bengal                  7022 (-19 to 12481)              -13.2% (-24.2 to 0%)           60895 (29712 to 107570)
 Nepal                       5341 (1607 to 10032)              -41% (-65.8 to -11%)            15455 (3199 to 33368)
 Pakistan                    9170 (2600 to 32238)            -47.5% (-73.8 to -27%)            17297 (9490 to 45445)
                                                   37

Location                                                                                                Cumulative deaths in reference
                                          Lives saved (95% UI)    Percent difference in deaths (95% UI)
                                                                                                             scenario (95% UI)
  Azad Jammu & Kashmir                      1312 (0 to 3255)             -66.2% (-96.6 to -0.5%)             1781 (64 to 4302)
  Balochistan                                884 (0 to 5894)             -49.6% (-94.6 to -0.3%)             1091 (141 to 6891)
  Gilgit-Baltistan                           349 (72 to 912)            -72.9% (-89.7 to -46.9%)             451 (152 to 1054)
  Islamabad Capital Territory               503 (233 to 776)            -49.8% (-66.8 to -25.3%)             1038 (516 to 1633)
  Khyber Pakhtunkhwa                         215 (27 to 920)              -12.4% (-40 to -2.1%)             1510 (1298 to 2373)
  Punjab                                    479 (51 to 2398)              -14% (-50.1 to -2.2%)             2728 (2265 to 4628)
  Sindh                                   5428 (975 to 23812)           -52.6% (-83.4 to -26.4%)            8697 (3709 to 31172)
Southeast Asia, East Asia, and Oceania    5600 (1897 to 11136)            -6.6% (-14.4 to -1.3%)          95856 (43874 to 175366)
 East Asia                                  2119 (1 to 6399)             -20.2% (-66.6 to -0.8%)            16367 (173 to 45930)
 China                                      2118 (0 to 6398)             -20.1% (-66.7 to -0.2%)            16357 (164 to 45920)
  Beijing                                       0 (0 to 0)                   0% (-0.1 to 0%)                    10 (10 to 10)
  Chongqing                                     0 (0 to 0)                   0% (-0.1 to 0%)                      7 (6 to 7)
  Guangdong                                     0 (0 to 0)                  -0.1% (-0.1 to 0%)                  10 (10 to 10)
  Hainan                                        0 (0 to 0)                   0% (-0.1 to 0%)                      7 (7 to 7)
  Hebei                                         0 (0 to 0)                   0% (-0.1 to 0%)                      7 (7 to 7)
  Heilongjiang                                  0 (0 to 0)                     0% (0 to 0%)                     15 (14 to 15)
  Hong Kong Special Administrative Region
of China                                    2118 (0 to 6398)             -20.8% (-70.7 to -0.2%)            16286 (92 to 45848)
  Shandong                                      0 (0 to 0)                  -0.1% (-0.1 to 0%)                    9 (9 to 9)
  Shanghai                                      0 (0 to 0)                  -0.1% (-0.1 to 0%)                    8 (8 to 8)
 Taiwan (Province of China)                     2 (0 to 5)               -15.3% (-35.7 to -5.7%)                 9 (8 to 13)
 Oceania                                        0 (0 to 1)                  -1.1% (-5.9 to 0%)                   9 (7 to 14)
 Guam                                           0 (0 to 1)                  -1.1% (-5.9 to 0%)                   9 (7 to 14)
 Southeast Asia                            3480 (410 to 6914)             -5.2% (-12.6 to -0.3%)          79480 (40114 to 139194)
 Indonesia                                3238 (1690 to 6213)           -20.6% (-30.9 to -13.9%)           15271 (11804 to 20779)
 Malaysia                                       0 (0 to 0)                     0% (0 to 0%)                   123 (123 to 124)
 Maldives                                    97 (34 to 171)             -47.1% (-69.2 to -26.4%)               214 (80 to 385)
 Mauritius                                      0 (0 to 0)                     0% (0 to 0%)                     11 (11 to 11)
 Myanmar                                        0 (0 to 0)                  -0.1% (-0.2 to 0%)                    7 (7 to 7)
                                                               38

Location                                                                                          Cumulative deaths in reference
                                   Lives saved (95% UI)     Percent difference in deaths (95% UI)
                                                                                                       scenario (95% UI)
 Philippines                        145 (-2641 to 1689)              -0.8% (-4.4 to 2.6%)           63785 (23465 to 125601)
 Sri Lanka                               0 (0 to 0)                   -0.1% (-0.3 to 0%)                  12 (11 to 13)
 Thailand                                0 (0 to 0)                      0% (0 to 0%)                     57 (57 to 58)
Sub-Saharan Africa                46883 (19950 to 88259)          -40.1% (-53.9 to -28.4%)          115886 (58348 to 198596)
 Central Sub-Saharan Africa          677 (183 to 1735)            -37.2% (-59.7 to -19.1%)             1705 (966 to 2926)
 Angola                                48 (7 to 136)               -19.6% (-38.2 to -5.1%)              219 (135 to 381)
 Central African Republic                0 (0 to 0)                     0% (-0.1 to 0%)                   61 (60 to 61)
 Congo                                135 (1 to 704)               -31.1% (-71.8 to -0.8%)              286 (93 to 1033)
 Democratic Republic of the Congo     246 (70 to 723)             -38.1% (-66.7 to -18.8%)             581 (368 to 1114)
 Equatorial Guinea                    248 (19 to 476)             -47.3% (-66.8 to -15.4%)              501 (125 to 940)
 Gabon                                   0 (0 to 1)                   -0.2% (-0.8 to 0%)                  56 (55 to 60)
 Eastern Sub-Saharan Africa       36329 (14053 to 69160)           -48% (-66.1 to -30.6%)           78765 (27000 to 151857)
 Comoros                                 0 (0 to 0)                     0% (-0.1 to 0%)                     7 (7 to 7)
 Djibouti                                0 (0 to 0)                      0% (0 to 0%)                     59 (59 to 60)
 Ethiopia                         28639 (9671 to 51209)            -60.6% (-78.8 to -40%)            48905 (16095 to 92152)
 Kenya                             2700 (100 to 10740)            -52.7% (-77.9 to -13.4%)            4355 (766 to 14289)
 Madagascar                           290 (8 to 1413)               -23.6% (-46 to -3.4%)              939 (229 to 3487)
 Malawi                               128 (3 to 516)               -25.9% (-59.4 to -1.7%)              381 (196 to 869)
 Mozambique                              3 (0 to 27)                -8.8% (-46.4 to -0.5%)                28 (22 to 57)
 Rwanda                              1074 (11 to 6945)            -66.4% (-88.5 to -24.7%)             1473 (42 to 10664)
 Somalia                                 0 (0 to 0)                      0% (0 to 0%)                     92 (92 to 92)
 South Sudan                             0 (0 to 0)                      0% (0 to 0%)                     47 (46 to 47)
 Uganda                            -108 (-5317 to 2423)              -5.1% (-35 to 23.1%)            17925 (1519 to 43838)
 United Republic of Tanzania       3569 (832 to 11986)            -80.4% (-94.4 to -63.4%)            4182 (1312 to 12706)
 Zambia                                32 (0 to 113)                -7.5% (-20.8 to -0.1%)              373 (281 to 545)
 Southern Sub-Saharan Africa        1935 (766 to 3645)               -8.2% (-13 to -4.2%)            22913 (18441 to 28851)
 Eswatini                             67 (26 to 119)              -19.3% (-26.6 to -12.5%)              337 (199 to 502)
 Lesotho                              145 (1 to 473)               -26.9% (-48.2 to -1.3%)              447 (43 to 1546)
                                                         39

Location                                                                                  Cumulative deaths in reference
                            Lives saved (95% UI)    Percent difference in deaths (95% UI)
                                                                                               scenario (95% UI)
 Namibia                       290 (79 to 545)            -30.3% (-43.8 to -19.9%)             987 (297 to 2073)
 South Africa                1360 (434 to 2792)              -6.3% (-11 to -2.5%)            20680 (16918 to 25940)
 Zimbabwe                       73 (5 to 287)               -13% (-25.9 to -2.4%)              461 (220 to 1137)
 Western Sub-Saharan Africa 7941 (2767 to 21231)          -59.6% (-80.7 to -40.3%)           12504 (6801 to 26726)
 Benin                            0 (0 to 0)                  -0.1% (-0.3 to 0%)                  41 (40 to 42)
 Burkina Faso                     0 (0 to 1)                  -0.2% (-1 to -0.1%)                 59 (58 to 61)
 Cabo Verde                    204 (0 to 615)               -47.1% (-91 to -0.5%)                331 (42 to 898)
 Cameroon                      149 (7 to 709)               -21% (-59.4 to -1.6%)              588 (426 to 1183)
 Chad                             0 (0 to 0)                    0% (-0.1 to 0%)                   74 (74 to 75)
 Cote d'Ivoire                431 (69 to 1811)             -65.5% (-91 to -34.7%)              578 (197 to 1948)
 Gambia                       527 (111 to 1007)           -51.9% (-71.8 to -28.9%)             985 (342 to 1767)
 Ghana                      3168 (148 to 13458)            -70.4% (-91 to -32.3%)             3994 (469 to 15532)
 Guinea                       1261 (0 to 7123)             -71.9% (-98.3 to -0.3%)             1370 (57 to 7761)
 Guinea-Bissau                 297 (2 to 1158)             -54.6% (-90.8 to -4.1%)              396 (49 to 1498)
 Liberia                        26 (0 to 394)                  -5.6% (-80 to 0%)                 109 (80 to 483)
 Mali                             0 (0 to 0)                    0% (-0.1 to 0%)                 128 (127 to 130)
 Mauritania                       0 (0 to 0)                     0% (0 to 0%)                   157 (157 to 158)
 Niger                            0 (0 to 0)                     0% (0 to 0%)                     70 (69 to 70)
 Nigeria                      471 (140 to 1001)            -28% (-45.6 to -11.4%)             1608 (1214 to 2233)
 Sao Tome and Principe           10 (0 to 80)              -21.4% (-78.2 to -0.2%)                26 (15 to 100)
 Senegal                     1239 (284 to 4326)           -65.6% (-87.3 to -42.9%)             1723 (634 to 5065)
 Sierra Leone                     0 (0 to 0)                  -0.1% (-0.1 to 0%)                  69 (69 to 70)
 Togo                          158 (0 to 1242)             -39.2% (-94.4 to -0.1%)              199 (27 to 1362)
                                                 40

medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
  (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                      It is made available under a CC-BY-NC-ND 4.0 International license .
    References
    1 Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. The
       Lancet Infectious Diseases 2020; 20: 533â€“4.
    2 World Health Organization. Advice on the use of masks in the context of COVID-19: Interim guidance.
       Geneva, Switzerland, 2020 https://apps.who.int/iris/bitstream/handle/10665/331693/WHO-2019-
       nCov-IPC_Masks-2020.3-eng.pdf?sequence=1&isAllowed=y.
    3 Greenhalgh T, Schmid MB, Czypionka T, Bassler D, Gruer L. Face masks for the public during the
       covid-19 crisis. BMJ 2020; 369. DOI:10.1136/bmj.m1435.
    4 Liang M, Gao L, Cheng C, et al. Efficacy of face mask in preventing respiratory virus transmission: A
       systematic review and meta-analysis. Travel Med Infect Dis 2020; published online May 28.
       DOI:10.1016/j.tmaid.2020.101751.
    5 Chu DK, Akl EA, Duda S, et al. Physical distancing, face masks, and eye protection to prevent person-
       to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. The
       Lancet 2020; 395: 1973â€“87.
    6 Community Initiatives. What Countries Require Masks in Public or Recommend Masks? #Masks4All.
       https://masks4all.co/what-countries-require-masks-in-public/ (accessed July 16, 2020).
    7 Andreoni M. Judge Scolds Brazilâ€™s President for Violating Mask Law. The New York Times. 2020;
       published online June 23. https://www.nytimes.com/2020/06/23/world/americas/bolsonaro-brazil-
       mask.html (accessed July 16, 2020).
    8 Aratani L. How did face masks become a political issue in America? the Guardian. 2020; published
       online June 29. http://www.theguardian.com/world/2020/jun/29/face-masks-us-politics-coronavirus
       (accessed July 16, 2020).
    9 Wang C, Otani Y. Removal of Nanoparticles from Gas Streams by Fibrous Filters: A Review. 2012;
       published online July 12. DOI:10.1021/ie300574m.
    10 Johnson E. Filtration Mechanisms of Particulate Respirators. 2005; : 7.
    11 World Health Organization. Transmission of SARS-CoV-2: implications for infection prevention
       precautions. Geneva, Switzerland, 2020 https://apps.who.int/iris/rest/bitstreams/1286634/retrieve.
    12 Fennelly KP. Particle sizes of infectious aerosols: implications for infection control. The Lancet
       Respiratory Medicine 2020; 0. DOI:10.1016/S2213-2600(20)30323-4.
    13 Rajagopalan S, Huang S, Brook RD. Flattening the curve in COVID-19 using personalised protective
       equipment: lessons from air pollution. Heart 2020; : heartjnl-2020-317104.
   14 MacIntyre CR, Chughtai AA. A rapid systematic review of the efficacy of face masks and respirators
       against coronaviruses and other respiratory transmissible viruses for the community, healthcare
       workers and sick patients. International Journal of Nursing Studies 2020; 108: 103629.
                                                                      41

medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
  (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                      It is made available under a CC-BY-NC-ND 4.0 International license .
    15 Morawska L, Cao J. Airborne transmission of SARS-CoV-2: The world should face the reality.
       Environment International 2020; 139: 105730.
    16 Wang Y, Tian H, Zhang L, et al. Reduction of secondary transmission of SARS-CoV-2 in households by
       face mask use, disinfection and social distancing: a cohort study in Beijing, China. BMJ Glob Health
       2020; 5: e002794.
    17 Chokephaibulkit K, Assanasen S, Apisarnthanarak A, et al. Seroprevalence of 2009 H1N1 Virus
       Infection and Self-Reported Infection Control Practices Among Healthcare Professionals Following the
       First Outbreak in Bangkok, Thailand. Influenza and Other Respiratory Viruses 2013; 7: 359â€“63.
    18 Cowling BJ, Fung ROP, Cheng CKY, et al. Preliminary Findings of a Randomized Trial of Non-
       Pharmaceutical Interventions to Prevent Influenza Transmission in Households. PLOS ONE 2008; 3:
       e2101.
    19 Cowling BJ, Chan K-H, Fang VJ, et al. Facemasks and Hand Hygiene to Prevent Influenza Transmission
       in Households. Annals of Internal Medicine 2009; 151: 437â€“46.
    20 MacIntyre CR, Wang Q, Cauchemez S, et al. A cluster randomized clinical trial comparing fit-tested
       and non-fit-tested N95 respirators to medical masks to prevent respiratory virus infection in health
       care workers. Influenza Other Respir Viruses 2011; 5: 170â€“9.
    21 Nishiura H, Kuratsuji T, Quy T, et al. Rapid awareness and transmission of severe acute respiratory
       syndrome in Hanoi French Hospital, Vietnam. Am J Trop Med Hyg 2005; 73: 17â€“25.
    22 Wilder-Smith A, Teleman MD, Heng BH, Earnest A, Ling AE, Leo YS. Asymptomatic SARS Coronavirus
       Infection among Healthcare Workers, Singapore. Emerging Infectious Diseases 2005; 11.
       DOI:10.3201/eid1107.041165.
    23 Teleman MD, Boudville IC, Heng BH, Zhu D, Leo YS. Factors associated with transmission of severe
       acute respiratory syndrome among health-care workers in Singapore. Epidemiology & Infection 2004;
       132: 797â€“803.
    24 Yin W, Gao L, Lin W, et al. [Effectiveness of personal protective measures in prevention of nosocomial
       transmission of severe acute respiratory syndrome]. Zhonghua Liu Xing Bing Xue Za Zhi 2004; 25: 18â€“
       22.
    25 Zhang Y, Seale H, Yang P, et al. Factors associated with the transmission of pandemic (H1N1) 2009
       among hospital healthcare workers in Beijing, China. Influenza Other Respir Viruses 2013; 7: 466â€“71.
    26 Lau JTF, Lau M, Kim JH, Tsui H-Y, Tsang T, Wong TW. Probable secondary infections in households of
       SARS patients in Hong Kong. Emerging Infect Dis 2004; 10: 235â€“43.
    27 Wu J, Xu F, Zhou W, et al. Risk Factors for SARS among Persons without Known Contact with SARS
       Patients, Beijing, China. Emerging Infectious Diseases 2004; 10. DOI:10.3201/eid1002.030730.
    28 Liu W, Tang F, Fang L-Q, et al. Risk factors for SARS infection among hospital healthcare workers in
       Beijing: a case control study. Tropical Medicine & International Health 2009; 14: 52â€“9.
                                                                      42

medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
  (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                      It is made available under a CC-BY-NC-ND 4.0 International license .
    29 Wang X, Pan Z, Cheng Z. Association between 2019-nCoV transmission and N95 respirator use. J Hosp
       Infect 2020; 105: 104â€“5.
    30 Wang Q, Huang X, Bai Y, et al. Epidemiological characteristics of COVID-19 in medical staff members
       of neurosurgery departments in Hubei province: A multicentre descriptive study. medRxiv 2020; :
       2020.04.20.20064899.
    31 Nishiyama A, Wakasugi N, Kirikae T, et al. Risk factors for SARS infection within hospitals in Hanoi,
       Vietnam. Jpn J Infect Dis 2008; 61: 388â€“90.
    32 Reynolds MG, Anh BH, Thu VH, et al. Factors associated with nosocomial SARS-CoV transmission
       among healthcare workers in Hanoi, Vietnam, 2003. BMC Public Health 2006; 6: 207.
    33 Seto WH, Tsang D, Yung RWH, et al. Effectiveness of precautions against droplets and contact in
       prevention of nosocomial transmission of severe acute respiratory syndrome (SARS). Lancet 2003;
       361: 1519â€“20.
    34 Ho KY, Singh KS, Habib AG, et al. Mild illness associated with severe acute respiratory syndrome
       coronavirus infection: lessons from a prospective seroepidemiologic study of health-care workers in a
       teaching hospital in Singapore. J Infect Dis 2004; 189: 642â€“7.
    35 Pei L, Gao Z, Yang Z, et al. Investigation of the influencing factors on severe acute respiratory
       syndrome among health care workers. Beijing Da Xue Xue Bao Yi Xue Ban 2006; 38: 271â€“5.
    36 Kim C-J, Choi WS, Jung Y, et al. Surveillance of the Middle East respiratory syndrome (MERS)
       coronavirus (CoV) infection in healthcare workers after contact with confirmed MERS patients:
       incidence and risk factors of MERS-CoV seropositivity. Clin Microbiol Infect 2016; 22: 880â€“6.
    37 Kim T, Jung J, Kim S-M, et al. Transmission among healthcare worker contacts with a Middle East
       respiratory syndrome patient in a single Korean centre. Clin Microbiol Infect 2016; 22: e11â€“3.
    38 Cheng VCC, Tai JWM, Wong LMW, et al. Prevention of nosocomial transmission of swine-origin
       pandemic influenza virus A/H1N1 by infection control bundle. Journal of Hospital Infection 2010; 74:
       271â€“7.
    39 Park J, Kim B, Chung K, Hwang Y. Factors associated with transmission of Middle East respiratory
       syndrome among Korean healthcare workers: infection control via extended healthcare contact
       management in a secondary outbreak hospital. Respirology 2016; 21: 89.
    40 Ki HK, Han SK, Son JS, Park SO. Risk of transmission via medical employees and importance of routine
       infection-prevention policy in a nosocomial outbreak of Middle East respiratory syndrome (MERS): a
       descriptive analysis from a tertiary care hospital in South Korea. BMC Pulmonary Medicine 2019; 19:
       190.
    41 Ha LD, Bloom SA, Hien NQ, et al. Lack of SARS Transmission among Public Hospital Workers, Vietnam.
       Emerg Infect Dis 2004; 10: 265â€“8.
    42 Tuan PA, Horby P, Dinh PN, et al. SARS transmission in Vietnam outside of the health-care setting.
       Epidemiol Infect 2007; 135: 392â€“401.
                                                                      43

medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
  (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                      It is made available under a CC-BY-NC-ND 4.0 International license .
    43 Loeb M, McGeer A, Henry B, et al. SARS among Critical Care Nurses, Toronto. Emerg Infect Dis 2004;
       10: 251â€“5.
    44 Scales DC, Green K, Chan AK, et al. Illness in Intensive Care Staff after Brief Exposure to Severe Acute
       Respiratory Syndrome. Emerg Infect Dis 2003; 9: 1205â€“10.
    45 Heinzerling A. Transmission of COVID-19 to Health Care Personnel During Exposures to a Hospitalized
       Patient â€” Solano County, California, February 2020. MMWR Morb Mortal Wkly Rep 2020; 69.
       DOI:10.15585/mmwr.mm6915e5.
    46 Park BJ, Peck AJ, Kuehnert MJ, et al. Lack of SARS Transmission among Healthcare Workers, United
       States. Emerg Infect Dis 2004; 10: 217â€“24.
    47 Peck AJ, Newbern EC, Feikin DR, et al. Lack of SARS transmission and U.S. SARS case-patient.
       Emerging Infect Dis 2004; 10: 217â€“24.
    48 Burke RM, Balter S, Barnes E, et al. Enhanced Contact Investigations for Nine Early Travel-Related
       Cases of SARS-CoV-2 in the United States. medRxiv 2020; : 2020.04.27.20081901.
    49 Barasheed O, Almasri N, Badahdah A-M, et al. Pilot Randomised Controlled Trial to Test Effectiveness
       of Facemasks in Preventing Influenza-like Illness Transmission among Australian Hajj Pilgrims in 2011.
       Infect Disord Drug Targets 2014; 14: 110â€“6.
    50 Suess T, Remschmidt C, Schink SB, et al. The role of facemasks and hand hygiene in the prevention of
       influenza transmission in households: results from a cluster randomised trial; Berlin, Germany, 2009-
       2011. BMC Infectious Diseases 2012; 12: 26.
    51 Sung AD, Sung JAM, Thomas S, et al. Universal Mask Usage for Reduction of Respiratory Viral
       Infections After Stem Cell Transplant: A Prospective Trial. Clin Infect Dis 2016; 63: 999â€“1006.
    52 Zhang L, Peng Z, Ou J, et al. Protection by Face Masks against Influenza A(H1N1)pdm09 Virus on
       Trans-Pacific Passenger Aircraft, 2009. Emerging Infectious Diseases 2013; 19.
       DOI:10.3201/eid1909.121765.
    53 Alraddadi BM, Al-Salmi HS, Jacobs-Slifka K, et al. Risk Factors for Middle East Respiratory Syndrome
       Coronavirus Infection among Healthcare Personnel. Emerg Infect Dis 2016; 22: 1915â€“20.
    54 Jaeger JL, Patel M, Dharan N, et al. Transmission of 2009 pandemic influenza A (H1N1) virus among
       healthcare personnel-Southern California, 2009. Infect Control Hosp Epidemiol 2011; 32: 1149â€“57.
    55 Hall AJ, Tokars JI, Badreddine SA, et al. Health care worker contact with MERS patient, Saudi Arabia.
       Emerging Infect Dis 2014; 20: 2148â€“51.
    56 Zhang L. Study on correlation between nosocomial respiratory virus infection and use of disposable
       respirator in medical staff. Nursing Practice and Research 2017; 14. DOI:10.3969/j.issn.1672-
       9676.2017.22.046.
    57 Aiello AE, Perez V, Coulborn RM, Davis BM, Uddin M, Monto AS. Facemasks, Hand Hygiene, and
       Influenza among Young Adults: A Randomized Intervention Trial. PLOS ONE 2012; 7: e29744.
                                                                      44

medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
  (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                      It is made available under a CC-BY-NC-ND 4.0 International license .
    58 Ryu B, Cho S-I, Oh M-D, et al. Seroprevalence of Middle East respiratory syndrome coronavirus
       (MERS-CoV) in public health workers responding to a MERS outbreak in Seoul, Republic of Korea, in
       2015. Western Pac Surveill Response J 2019; 10: 46â€“8.
    59 Ma H, Wang H, Fang L, et al. [A case-control study on the risk factors of severe acute respiratory
       syndromes among health care workers]. Zhonghua Liu Xing Bing Xue Za Zhi 2004; 25: 741â€“4.
    60 Zheng P, Aravkin A, Barber R, Sorensen R, Murray C. Trimmed Constrained Mixed Effects Models:
       Formulations and Algorithms. Bioinformatics, 2020 DOI:10.1101/2020.01.28.923599.
    61 Fan J, Li Y, Stewart K, et al. COVID-19 World Survey Data API. 2020.
       https://covidmap.umd.edu/api.html (accessed July 19, 2020).
    62 Huprikar S, Ludolph T. Are Americans Wearing Face Masks? Premise. 2020; published online June 4.
       https://www.premise.com/are-americans-wearing-face-masks/ (accessed July 16, 2020).
    63 Jones SP, Imperial College London Big Data Analytical Unit, YouGov PIc. YouGov Covid Data Hub, v1.0.
       YouGov PIc., 2020 https://github.com/YouGov-Data/covid-19-tracker (accessed July 19, 2020).
    64 Reiner Jr. R, Barber R, Zheng P, et al. COVID-19 scenarios for the United States. Infectious Diseases
       (except HIV/AIDS), 2020 DOI:10.1101/2020.07.12.20151191.
    65 Roth GA, Abate D, Abate KH, et al. Global, regional, and national age-sex-specific mortality for 282
       causes of death in 195 countries and territories, 1980â€“2017: a systematic analysis for the Global
       Burden of Disease Study 2017. The Lancet 2018; 392: 1736â€“88.
    66 Friedman J, Liu P, Gakidou E, IHME COVID-19 Model Comparison Team. Predictive performance of
       international COVID-19 mortality forecasting models. Epidemiology, 2020
       DOI:10.1101/2020.07.13.20151233.
    67 Davis N. Report on face masksâ€™ effectiveness for Covid-19 divides scientists. The Guardian. 2020;
       published online May 4. https://www.theguardian.com/world/2020/may/04/scientists-disagree-
       over-face-masks-effect-on-covid-19 (accessed July 16, 2020).
    68 Face Masks for the General Public. Royal Society DELVE Initiative. 2020; published online May 4.
       http://rs-delve.github.io/reports/2020/05/04/face-masks-for-the-general-public.html (accessed July
       16, 2020).
   69 Wang Y, Tian H, Zhang L, et al. Reduction of secondary transmission of SARS-CoV-2 in households by
       face mask use, disinfection and social distancing: a cohort study in Beijing, China. BMJ Glob Health
       2020; 5: e002794.
   70 Leung NHL, Chu DKW, Shiu EYC, et al. Respiratory virus shedding in exhaled breath and efficacy of
       face masks. Nature Medicine 2020; 26: 676â€“80.
   71 Hendrix MJ. Absence of Apparent Transmission of SARS-CoV-2 from Two Stylists After Exposure at a
       Hair Salon with a Universal Face Covering Policy â€” Springfield, Missouri, May 2020. MMWR Morb
       Mortal Wkly Rep 2020; 69. DOI:10.15585/mmwr.mm6928e2.
                                                                      45

medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
  (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                      It is made available under a CC-BY-NC-ND 4.0 International license .
    72 Bielecki M, ZÃ¼st R, Siegrist D, et al. Social distancing alters the clinical course of COVID-19 in young
       adults: A comparative cohort study. Clinical Infectious Diseases 2020; : ciaa889.
    73 Wang X, Ferro EG, Zhou G, Hashimoto D, Bhatt DL. Association Between Universal Masking in a
       Health Care System and SARS-CoV-2 Positivity Among Health Care Workers. JAMA 2020; published
       online July 14. DOI:10.1001/jama.2020.12897.
    74 CDC. Coronavirus Disease 2019 (COVID-19) : Use of masks to help slow the spread of COVID-19.
       Centers for Disease Control and Prevention. 2020; published online Feb 11.
       https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/diy-cloth-face-coverings.html
       (accessed Aug 2, 2020).
    75 Iversen BG, Vestrheim D, Flottorp S, Denison E, Oxman A, Norwegian Institute of Public Health.
       Should individuals in the community without respiratory symptoms wear facemasks to reduce the
       spread of COVID-19? Norwegian Institude of Public Health 2020; : 45.
    76 Zaken M van A. Avoid busy places and stay 1.5 metres away from others. 2020; published online May
       6. https://www.government.nl/latest/news/2020/05/06/avoid-busy-places-and-stay-1.5-metres-
       away-from-others (accessed July 16, 2020).
    77 The Public Health Agency of Sweden. FAQ about COVID-19.
       http://www.folkhalsomyndigheten.se/the-public-health-agency-of-sweden/communicable-disease-
       control/covid-19/ (accessed July 16, 2020).
   78 Wong T. Coronavirus: Why some countries wear face masks and others donâ€™t - BBC News.
       https://www.bbc.com/news/world-52015486 (accessed July 16, 2020).
   79 World Health Organization. Advice on the use of masks in the context of COVID-19: Interim guidance.
       Geneva, Switzerland, 2020 https://apps.who.int/iris/bitstream/handle/10665/332293/WHO-2019-
       nCov-IPC_Masks-2020.4-eng.pdf?sequence=1&isAllowed=y.
                                                                      46

medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209510.this version posted October 11, 2020. The copyright holder for this preprint
  (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                      It is made available under a CC-BY-NC-ND 4.0 International license .
    Code Availability Statement
    Our study follows the Guidelines for Accurate and Transparent Health Estimate Reporting. All code used
    for these analyses is publicly available online (http://github.com/ihmeuw/).
    Online content
    Results for each scenario are accessible through a visualization tool at http://covid19.healthdata.org.
    The estimates presented in this tool will be iteratively updated as new data are incorporated and will
    ultimately supersede the results in this paper.
    Acknowledgments
    We thank the various Departments of Health and frontline health professionals who are not only
    responding to this epidemic daily, but also provide the necessary data to inform this work â€“ IHME wishes
    to warmly acknowledge the support of these and others
    (http://www.healthdata.org/covid/acknowledgements) who have made our COVID-19 estimation
    efforts possible. This work was supported by the Bill & Melinda Gates Foundation, Bloomberg
    Philanthropies, as well as funding from the state of Washington and the National Science Foundation
    (2031096). We also extend a note of particular thanks to John Stanton and Julie Nordstrom for their
    generous support. We are grateful to Professor Wei Huang from Peking University for helping us extract
    information from scientific papers in Chinese.
    Competing interests
    This study was funded by the Bill & Melinda Gates Foundation and Bloomberg Philanthropies. The
    funders of the study had no role in study design, data collection, data analysis, data interpretation,
    writing of the final report, or decision to publish. The corresponding author had full access to all of the
    data in the study and had final responsibility for the decision to submit for publication.
                                                                      47
